aripiprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychotropics, phenylpiperazine derivatives 242 129722-12-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aripiprazole hydrate
  • aripiprazole
  • abilify
  • arpizol
  • pripiprazole
  • OPC-14597
A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.
  • Molecular weight: 448.39
  • Formula: C23H27Cl2N3O2
  • CLOGP: 5.11
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 44.81
  • ALOGS: -4.76
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P
13.30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.56 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.83 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 75 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2006 PMDA Otsuka Pharmaceutical Co., Ltd
June 4, 2004 EMA
Nov. 15, 2002 FDA OTSUKA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tardive dyskinesia 1538.42 11.74 538 80280 6741 50517565
Akathisia 1388.91 11.74 515 80303 7714 50516592
Dystonia 1063.49 11.74 472 80346 11454 50512852
Extrapyramidal disorder 895.22 11.74 417 80401 11353 50512953
Suicide attempt 802.44 11.74 663 80155 51069 50473237
Dyskinesia 745.72 11.74 496 80322 27365 50496941
Sedation 729.08 11.74 507 80311 30103 50494203
Psychotic disorder 686.47 11.74 430 80388 21382 50502924
Weight increased 679.25 11.74 1181 79637 200710 50323596
Sexual dysfunction 648.39 11.74 231 80587 3061 50521245
Suicidal ideation 644.53 11.74 603 80215 54782 50469524
Blood prolactin abnormal 626.53 11.74 203 80615 1972 50522334
Product use in unapproved indication 615.70 11.74 838 79980 114981 50409325
Neuroleptic malignant syndrome 606.00 11.74 314 80504 10816 50513490
Parkinsonism 591.82 11.74 287 80531 8560 50515746
Delusion 552.05 11.74 290 80528 10279 50514027
Hallucination, auditory 536.67 11.74 286 80532 10442 50513864
Mania 520.82 11.74 282 80536 10634 50513672
Anosognosia 510.00 11.74 175 80643 2059 50522247
Drug interaction 468.34 11.74 1003 79815 198618 50325688
Treatment noncompliance 466.32 11.74 386 80432 29764 50494542
Disturbance in social behaviour 462.12 11.74 174 80644 2720 50521586
Tremor 435.88 11.74 710 80108 114193 50410113
Hyperprolactinaemia 412.42 11.74 167 80651 3198 50521108
Metabolic disorder 397.85 11.74 186 80632 5100 50519206
Personality change 353.21 11.74 175 80643 5470 50518836
Intentional self-injury 349.24 11.74 292 80526 22820 50501486
Oculogyric crisis 329.70 11.74 113 80705 1324 50522982
Restlessness 327.58 11.74 292 80526 24881 50499425
Abnormal behaviour 315.04 11.74 257 80561 19401 50504905
Schizoaffective disorder 296.44 11.74 117 80701 2089 50522217
Intentional overdose 288.28 11.74 423 80395 62081 50462225
Electrocardiogram QT prolonged 285.20 11.74 382 80436 51504 50472802
Prescribed underdose 262.92 11.74 212 80606 15737 50508569
Agitation 261.81 11.74 372 80446 53012 50471294
Maternal exposure during pregnancy 260.78 11.74 698 80120 159080 50365226
Anxiety 254.55 11.74 740 80078 176866 50347440
Schizophrenia 248.24 11.74 152 80666 7245 50517061
Aggression 245.54 11.74 230 80588 20886 50503420
Stubbornness 238.26 11.74 61 80757 224 50524082
Psychiatric decompensation 235.38 11.74 85 80733 1173 50523133
Arthralgia 231.92 11.74 216 80602 438486 50085820
Pain 229.84 11.74 357 80461 578546 49945760
Muscle rigidity 220.35 11.74 157 80661 9672 50514634
Somnolence 218.38 11.74 642 80176 154343 50369963
Gambling disorder 217.14 11.74 79 80739 1115 50523191
Joint swelling 216.11 11.74 62 80756 245224 50279082
Galactorrhoea 214.06 11.74 109 80709 3614 50520692
Psychotic symptom 212.28 11.74 78 80740 1134 50523172
Salivary hypersecretion 209.91 11.74 131 80687 6460 50517846
Blood prolactin increased 205.60 11.74 100 80718 2999 50521307
Diarrhoea 198.23 11.74 402 80416 588074 49936232
Infusion related reaction 189.01 11.74 24 80794 169533 50354773
Irritability 183.96 11.74 227 80591 28199 50496107
Rheumatoid arthritis 182.47 11.74 49 80769 202501 50321805
Swelling 182.08 11.74 48 80770 200824 50323482
Contraindicated product administered 179.01 11.74 16 80802 148942 50375364
Blood glucose increased 177.86 11.74 368 80450 70956 50453350
Abortion spontaneous 175.84 11.74 271 80547 41501 50482805
Systemic lupus erythematosus 174.82 11.74 13 80805 140609 50383697
Dyspnoea 174.34 11.74 386 80432 547222 49977084
Gestational diabetes 171.40 11.74 121 80697 7344 50516962
Thinking abnormal 165.85 11.74 131 80687 9436 50514870
Abdominal discomfort 157.51 11.74 87 80731 231554 50292752
Psychomotor hyperactivity 154.06 11.74 124 80694 9177 50515129
Rash 153.82 11.74 291 80527 437180 50087126
Psychiatric symptom 153.58 11.74 94 80724 4476 50519830
Depression 152.95 11.74 595 80223 164828 50359478
Foetal exposure during pregnancy 152.66 11.74 203 80615 27156 50497150
Prescribed overdose 152.64 11.74 150 80668 14450 50509856
Arthropathy 152.37 11.74 33 80785 157873 50366433
Drug level increased 148.05 11.74 168 80650 19100 50505206
Overdose 146.95 11.74 420 80398 99307 50424999
Glossodynia 145.60 11.74 10 80808 115559 50408747
Pregnancy 144.77 11.74 206 80612 29371 50494935
Mental disorder 142.90 11.74 176 80642 21815 50502491
Drug monitoring procedure incorrectly performed 142.85 11.74 35 80783 102 50524204
Metabolic syndrome 141.87 11.74 60 80758 1287 50523019
Orthostatic hypertension 141.05 11.74 43 80775 335 50523971
Suppressed lactation 139.54 11.74 44 80774 388 50523918
Drug intolerance 138.13 11.74 90 80728 219014 50305292
Underdose 136.16 11.74 165 80653 20113 50504193
Insurance issue 133.25 11.74 70 80748 2478 50521828
Persecutory delusion 131.77 11.74 68 80750 2319 50521987
Pneumonia 130.92 11.74 254 80564 378147 50146159
Diabetes mellitus 128.13 11.74 258 80560 48775 50475531
Sinusitis 124.96 11.74 58 80760 170500 50353806
Drug abuse 123.28 11.74 286 80532 59560 50464746
Off label use 121.61 11.74 1223 79595 473203 50051103
Hypomania 119.92 11.74 80 80738 4425 50519881
Anaemia 117.66 11.74 138 80680 252318 50271988
Social avoidant behaviour 116.23 11.74 66 80752 2731 50521575
Caesarean section 116.16 11.74 134 80684 15505 50508801
Catatonia 115.81 11.74 73 80745 3663 50520643
Alopecia 115.22 11.74 133 80685 244914 50279392
Cogwheel rigidity 113.86 11.74 56 80762 1721 50522585
Hypersexuality 113.18 11.74 38 80780 416 50523890
Cough 108.06 11.74 136 80682 241128 50283178
Hypersensitivity 107.53 11.74 111 80707 215050 50309256
Wrong technique in product usage process 106.44 11.74 258 80560 55252 50469054
Logorrhoea 105.17 11.74 58 80760 2266 50522040
Infarction 105.08 11.74 58 80760 2270 50522036
Antipsychotic drug level increased 104.60 11.74 64 80754 3045 50521261
Fatigue 104.40 11.74 683 80135 706918 49817388
Mood altered 102.62 11.74 114 80704 12659 50511647
Normal newborn 101.99 11.74 85 80733 6606 50517700
Nasopharyngitis 101.62 11.74 95 80723 192832 50331474
Febrile neutropenia 101.42 11.74 17 80801 97650 50426656
Hallucination 99.42 11.74 226 80592 46431 50477875
Hostility 99.04 11.74 51 80767 1731 50522575
Blood creatine phosphokinase increased 97.12 11.74 161 80657 26206 50498100
Personality disorder 96.75 11.74 69 80749 4255 50520051
Paranoia 96.59 11.74 100 80718 10248 50514058
Compulsive shopping 96.18 11.74 38 80780 680 50523626
Economic problem 93.60 11.74 50 80768 1832 50522474
Impulsive behaviour 93.58 11.74 46 80772 1412 50522894
Muscle twitching 93.08 11.74 119 80699 15312 50508994
Infection 92.45 11.74 84 80734 172870 50351436
Discomfort 92.41 11.74 29 80789 108351 50415955
Drug hypersensitivity 91.54 11.74 163 80655 250847 50273459
Mental impairment 90.80 11.74 104 80714 11940 50512366
Posture abnormal 88.71 11.74 50 80768 2039 50522267
Disease progression 88.53 11.74 22 80796 95844 50428462
Amenorrhoea 88.37 11.74 87 80731 8397 50515909
Impaired healing 87.99 11.74 6 80812 69780 50454526
Premature delivery 85.16 11.74 143 80675 23520 50500786
Impulse-control disorder 84.67 11.74 34 80784 636 50523670
Rabbit syndrome 84.61 11.74 28 80790 292 50524014
Urinary incontinence 84.14 11.74 157 80661 28051 50496255
Peripheral swelling 83.22 11.74 125 80693 205811 50318495
Drooling 82.70 11.74 57 80761 3327 50520979
Obsessive-compulsive disorder 81.02 11.74 56 80762 3284 50521022
Serotonin syndrome 80.63 11.74 143 80675 24570 50499736
Pruritus 80.32 11.74 212 80606 283356 50240950
Disinhibition 78.44 11.74 34 80784 776 50523530
Apathy 77.87 11.74 77 80741 7471 50516835
Therapeutic product effect decreased 76.43 11.74 63 80755 135987 50388319
Bipolar disorder 75.47 11.74 72 80746 6685 50517621
Lower respiratory tract infection 75.08 11.74 29 80789 95172 50429134
Obesity 75.05 11.74 112 80706 16663 50507643
Sopor 72.69 11.74 121 80697 19758 50504548
Dysarthria 71.85 11.74 174 80644 37229 50487077
Stomatitis 71.83 11.74 36 80782 101308 50422998
Hyperphagia 71.44 11.74 39 80779 1493 50522813
Back pain 71.42 11.74 153 80665 219877 50304429
Malignant neoplasm progression 70.40 11.74 12 80806 68112 50456194
Pain in extremity 69.89 11.74 214 80604 272651 50251655
Abortion 69.61 11.74 43 80775 2081 50522225
Gaze palsy 67.94 11.74 36 80782 1297 50523009
Increased appetite 67.81 11.74 75 80743 8286 50516020
Hallucinations, mixed 66.46 11.74 54 80764 4049 50520257
Abortion induced 65.95 11.74 78 80740 9266 50515040
Seizure 65.79 11.74 366 80452 117508 50406798
Completed suicide 65.48 11.74 397 80421 131492 50392814
Depressed mood 65.05 11.74 158 80660 33865 50490441
Exposure during pregnancy 64.41 11.74 371 80447 120644 50403662
Live birth 64.23 11.74 103 80715 16305 50508001
Gambling 63.81 11.74 21 80797 215 50524091
Treatment failure 63.22 11.74 76 80742 137561 50386745
Thrombocytopenia 62.45 11.74 67 80751 127606 50396700
Nausea 62.43 11.74 775 80043 704623 49819683
Pericarditis 62.00 11.74 24 80794 78665 50445641
Disturbance in attention 61.96 11.74 147 80671 31039 50493267
Stupor 61.96 11.74 49 80769 3534 50520772
Gastrointestinal disorder 61.93 11.74 37 80781 94419 50429887
Blister 61.05 11.74 30 80788 85388 50438918
Bipolar I disorder 60.87 11.74 35 80783 1483 50522823
Insomnia 60.04 11.74 481 80337 174384 50349922
Affective disorder 59.37 11.74 56 80762 5125 50519181
Hypothermia 59.24 11.74 84 80734 11932 50512374
Sinus tachycardia 57.72 11.74 114 80704 21240 50503066
Pyrexia 57.31 11.74 364 80454 379839 50144467
Abdominal pain 57.16 11.74 190 80628 236038 50288268
Urinary retention 57.04 11.74 128 80690 26062 50498244
Symptom recurrence 56.44 11.74 26 80792 688 50523618
Libido increased 56.19 11.74 31 80787 1212 50523094
Neuropathy peripheral 55.33 11.74 44 80774 96713 50427593
Compulsive sexual behaviour 54.98 11.74 14 80804 50 50524256
Hepatic enzyme increased 54.87 11.74 84 80734 137296 50387010
Anger 54.07 11.74 78 80740 11255 50513051
Osteoarthritis 53.92 11.74 21 80797 68585 50455721
Herpes zoster 53.48 11.74 23 80795 70763 50453543
Arthritis 52.72 11.74 37 80781 86684 50437622
General physical health deterioration 52.30 11.74 92 80726 142342 50381964
Flat affect 52.09 11.74 30 80788 1275 50523031
Soliloquy 51.57 11.74 17 80801 175 50524131
Atrial fibrillation 51.32 11.74 52 80766 101693 50422613
Folliculitis 50.55 11.74 3 80815 39222 50485084
Mutism 50.52 11.74 30 80788 1351 50522955
Inappropriate affect 50.42 11.74 25 80793 782 50523524
Enuresis 50.01 11.74 35 80783 2094 50522212
Pregnancy on contraceptive 49.66 11.74 27 80791 1025 50523281
Depressive symptom 49.49 11.74 41 80777 3159 50521147
Bruxism 49.22 11.74 40 80778 3000 50521306
Musculoskeletal pain 49.13 11.74 27 80791 72150 50452156
Urticaria 49.11 11.74 82 80736 129479 50394827
Mood swings 49.08 11.74 90 80728 15864 50508442
Euphoric mood 48.72 11.74 45 80773 4010 50520296
Cardiac failure congestive 48.71 11.74 38 80780 84344 50439962
Rhabdomyolysis 48.59 11.74 155 80663 38872 50485434
Trimethylaminuria 48.53 11.74 15 80803 123 50524183
Restless legs syndrome 48.05 11.74 89 80729 15808 50508498
Threatened labour 48.05 11.74 24 80794 763 50523543
Right ventricular false tendon 47.50 11.74 10 80808 10 50524296
Vertigo 47.43 11.74 186 80632 51646 50472660
Newborn persistent pulmonary hypertension 47.30 11.74 15 80803 135 50524171
Meconium aspiration syndrome 47.01 11.74 10 80808 11 50524295
Hospitalisation 46.96 11.74 224 80594 67713 50456593
Bankruptcy 46.85 11.74 11 80807 25 50524281
Tic 45.99 11.74 27 80791 1190 50523116
Erythema 45.67 11.74 104 80714 146310 50377996
Irritable bowel syndrome 45.22 11.74 13 80805 51428 50472878
Rhesus incompatibility 45.15 11.74 13 80805 81 50524225
Wound 44.87 11.74 62 80756 105732 50418574
Coma 44.87 11.74 195 80623 56684 50467622
Muscle injury 44.50 11.74 4 80814 37107 50487199
Abdominal pain upper 44.35 11.74 120 80698 159189 50365117
Memory impairment 43.97 11.74 246 80572 79114 50445192
Parkinsonian rest tremor 43.73 11.74 13 80805 92 50524214
Slow response to stimuli 42.97 11.74 23 80795 846 50523460
Paradoxical drug reaction 42.91 11.74 40 80778 3607 50520699
Psychotic behaviour 42.61 11.74 20 80798 553 50523753
Substance abuse 42.41 11.74 42 80776 4082 50520224
Sepsis 41.80 11.74 94 80724 132831 50391475
Pleural effusion 41.80 11.74 41 80777 81413 50442893
Affect lability 41.57 11.74 61 80757 8937 50515369
Drug screen false positive 41.41 11.74 22 80796 797 50523509
Mobility decreased 41.30 11.74 40 80778 79908 50444398
Blunted affect 41.14 11.74 15 80803 213 50524093
Resting tremor 40.99 11.74 21 80797 705 50523601
Dysphagia 40.79 11.74 237 80581 77281 50447025
Ascites 40.10 11.74 5 80813 35856 50488450
Poisoning deliberate 40.02 11.74 56 80762 7856 50516450
Acute kidney injury 39.84 11.74 208 80610 227850 50296456
Platelet count decreased 39.81 11.74 62 80756 100664 50423642
Acute psychosis 39.77 11.74 31 80787 2189 50522117
Psychomotor skills impaired 39.55 11.74 30 80788 2034 50522272
Accidental exposure to product by child 39.11 11.74 23 80795 1017 50523289
Altered state of consciousness 38.98 11.74 99 80719 21811 50502495
Lactation disorder 38.95 11.74 16 80802 318 50523988
Depressed level of consciousness 38.63 11.74 175 80643 51778 50472528
Thermal burn 38.52 11.74 43 80775 4798 50519508
Decreased appetite 38.11 11.74 178 80640 200745 50323561
Blepharospasm 37.93 11.74 34 80784 2914 50521392
Parkinsonian gait 37.79 11.74 17 80801 425 50523881
Blood triglycerides increased 37.59 11.74 66 80752 11246 50513060
Mucosal inflammation 37.46 11.74 9 80809 40133 50484173
Eye movement disorder 37.25 11.74 41 80777 4504 50519802
Colitis 37.23 11.74 8 80810 38521 50485785
Injection site erythema 36.99 11.74 39 80779 74897 50449409
Death 36.91 11.74 337 80481 325042 50199264
Pleurothotonus 36.80 11.74 24 80794 1277 50523029
Alice in wonderland syndrome 36.79 11.74 9 80809 26 50524280
Bradyphrenia 36.40 11.74 47 80771 6105 50518201
Upper respiratory tract infection 36.39 11.74 31 80787 65867 50458439
Neuropsychiatric symptoms 36.36 11.74 18 80800 561 50523745
Binge eating 36.29 11.74 16 80802 381 50523925
Headache 35.97 11.74 581 80237 505954 50018352
Asthenia 35.94 11.74 331 80487 318711 50205595
Haemoglobin decreased 35.27 11.74 96 80722 127120 50397186
Skin ulcer 34.81 11.74 7 80811 35311 50488995
Personal relationship issue 34.75 11.74 9 80809 35 50524271
Conversion disorder 34.63 11.74 25 80793 1571 50522735
Hypertonia 34.59 11.74 37 80781 3936 50520370
Somnambulism 34.57 11.74 41 80777 4883 50519423
Morbid thoughts 34.49 11.74 17 80801 525 50523781
Gastrointestinal haemorrhage 34.17 11.74 40 80778 73281 50451025
Hypokinesia 33.96 11.74 66 80752 12151 50512155
Hallucination, olfactory 33.84 11.74 13 80805 215 50524091
Neonatal hypotension 33.56 11.74 11 80807 111 50524195
C-reactive protein abnormal 33.34 11.74 3 80815 27806 50496500
Wheezing 33.28 11.74 30 80788 62017 50462289
Homicidal ideation 33.19 11.74 25 80793 1677 50522629
Tachyphrenia 32.87 11.74 22 80796 1223 50523083
Reduced facial expression 32.40 11.74 24 80794 1570 50522736
Cognitive disorder 32.33 11.74 148 80670 43975 50480331
Suicidal behaviour 32.19 11.74 28 80790 2306 50522000
Abulia 32.05 11.74 15 80803 412 50523894
Delirium 31.71 11.74 133 80685 38059 50486247
Knee arthroplasty 31.61 11.74 9 80809 35837 50488469
Bradykinesia 31.34 11.74 35 80783 3908 50520398
Electroencephalogram abnormal 31.20 11.74 33 80785 3466 50520840
Ill-defined disorder 31.05 11.74 25 80793 54629 50469677
Antipsychotic drug level decreased 31.05 11.74 12 80806 202 50524104
Osteonecrosis of jaw 30.93 11.74 7 80811 32519 50491787
Bronchitis 30.86 11.74 76 80742 104083 50420223
Birdshot chorioretinopathy 30.61 11.74 9 80809 61 50524245
Stereotypy 30.48 11.74 14 80804 368 50523938
Target skin lesion 30.24 11.74 10 80808 104 50524202
Sexually inappropriate behaviour 30.24 11.74 10 80808 104 50524202
Septic shock 30.24 11.74 28 80790 57147 50467159
Productive cough 30.07 11.74 24 80794 52670 50471636
Vomiting 29.93 11.74 537 80281 460221 50064085
Breast feeding 29.92 11.74 18 80800 830 50523476
Drug withdrawal syndrome 29.76 11.74 98 80720 24983 50499323
Dyspnoea exertional 29.65 11.74 23 80795 51210 50473096
Poor feeding infant 29.52 11.74 12 80806 232 50524074
Melaena 29.42 11.74 4 80814 26860 50497446
Soft tissue injury 29.39 11.74 22 80796 1462 50522844
Plasma cell myeloma 29.27 11.74 7 80811 31315 50492991
Disease recurrence 28.97 11.74 84 80734 19997 50504309
Product substitution issue 28.72 11.74 67 80751 13990 50510316
Contusion 28.65 11.74 88 80730 112095 50412211
Crying 28.12 11.74 84 80734 20332 50503974
Chemical burn 28.08 11.74 13 80805 348 50523958
Antipsychotic drug level above therapeutic 27.89 11.74 18 80800 941 50523365
Breech presentation 27.78 11.74 19 80799 1095 50523211
Withdrawal syndrome 27.75 11.74 76 80742 17514 50506792
Hypoventilation neonatal 27.71 11.74 7 80811 24 50524282
Grandiosity 27.64 11.74 12 80806 275 50524031
Epistaxis 27.59 11.74 37 80781 63917 50460389
Multiple organ dysfunction syndrome 27.40 11.74 24 80794 50313 50473993
Compulsive hoarding 27.36 11.74 8 80810 53 50524253
Trismus 27.09 11.74 30 80788 3318 50520988
Nuchal rigidity 27.01 11.74 15 80803 594 50523712
Femur fracture 27.00 11.74 13 80805 37451 50486855
Renal failure 26.98 11.74 84 80734 106549 50417757
Uterine dilation and curettage 26.93 11.74 17 80801 855 50523451
Agitation neonatal 26.82 11.74 14 80804 489 50523817
Nephrogenic diabetes insipidus 26.77 11.74 17 80801 864 50523442
Hypercalcaemia 26.74 11.74 3 80815 23349 50500957
Red blood cell sedimentation rate increased 26.66 11.74 7 80811 29409 50494897
Movement disorder 26.64 11.74 75 80743 17557 50506749
Miosis 26.62 11.74 41 80777 6269 50518037
Ideas of reference 26.60 11.74 9 80809 101 50524205
Persistent depressive disorder 26.59 11.74 17 80801 874 50523432
Apraxia 26.44 11.74 21 80797 1524 50522782
Granulocytopenia 26.42 11.74 37 80781 5194 50519112
Divorced 26.42 11.74 6 80812 11 50524295
Myoclonus 26.38 11.74 66 80752 14404 50509902
Torticollis 26.34 11.74 22 80796 1714 50522592
Diverticulitis 26.33 11.74 10 80808 33172 50491134
Sinus rhythm 26.32 11.74 15 80803 625 50523681
Neoplasm progression 26.31 11.74 7 80811 29150 50495156
Hereditary ataxia 26.30 11.74 7 80811 31 50524275
Injection site pruritus 26.24 11.74 16 80802 40395 50483911
Osteoporosis 26.16 11.74 20 80798 44859 50479447
Oropharyngeal pain 26.13 11.74 53 80765 77748 50446558
Psoriatic arthropathy 26.12 11.74 22 80796 47010 50477296
Pulmonary artery stenosis congenital 26.05 11.74 11 80807 235 50524071
Pancytopenia 25.93 11.74 60 80758 83970 50440336
Inappropriate schedule of product administration 25.93 11.74 200 80618 71631 50452675
Behaviour disorder 25.89 11.74 25 80793 2355 50521951
Nightmare 25.87 11.74 70 80748 16016 50508290
Choroiditis 25.62 11.74 9 80809 114 50524192
Hepatotoxicity 25.61 11.74 6 80812 27220 50497086
Paraesthesia 25.55 11.74 102 80716 120141 50404165
Inflammation 25.51 11.74 32 80786 56880 50467426
Hyperhidrosis 25.41 11.74 236 80582 89190 50435116
Self-injurious ideation 25.36 11.74 24 80794 2205 50522101
Major depression 25.29 11.74 42 80776 6842 50517464
Chorioretinopathy 25.25 11.74 16 80802 810 50523496
Coronary artery disease 25.24 11.74 8 80810 29718 50494588
Bundle branch block right 25.19 11.74 34 80784 4611 50519695
Bone pain 25.13 11.74 23 80795 47206 50477100
Premature labour 24.89 11.74 56 80762 11420 50512886
Accommodation disorder 24.88 11.74 12 80806 353 50523953
Myocarditis 24.66 11.74 45 80773 7902 50516404
Megacolon 24.61 11.74 21 80797 1685 50522621
Drug monitoring procedure not performed 24.59 11.74 13 80805 466 50523840
Post-traumatic neck syndrome 24.52 11.74 22 80796 1888 50522418
Blood pressure systolic increased 24.50 11.74 13 80805 35436 50488870
Hip arthroplasty 24.43 11.74 9 80809 30420 50493886
Injection site pain 24.34 11.74 93 80725 110931 50413375
Fluid retention 24.28 11.74 27 80791 50622 50473684
Dry skin 24.23 11.74 20 80798 43171 50481135
Rebound psychosis 23.88 11.74 6 80812 20 50524286
Physical assault 23.87 11.74 16 80802 892 50523414
Sleep disorder 23.83 11.74 165 80653 57118 50467188
Gastric ulcer 23.75 11.74 3 80815 21302 50503004
Morning sickness 23.68 11.74 14 80804 625 50523681
Microphthalmos 23.65 11.74 9 80809 145 50524161
Distractibility 23.64 11.74 12 80806 395 50523911
Injection site reaction 23.63 11.74 27 80791 50005 50474301
Type 2 diabetes mellitus 23.50 11.74 113 80705 34262 50490044
Personality change due to a general medical condition 23.39 11.74 8 80810 93 50524213
Haemoptysis 23.34 11.74 6 80812 25567 50498739
Psychomotor retardation 23.24 11.74 28 80790 3390 50520916
Verbal abuse 23.24 11.74 8 80810 95 50524211
Facial nerve disorder 23.00 11.74 13 80805 533 50523773
Generalised tonic-clonic seizure 22.92 11.74 93 80725 26217 50498089
Cholestasis of pregnancy 22.92 11.74 17 80801 1114 50523192
Tachycardia 22.92 11.74 252 80566 99511 50424795
Negative symptoms in schizophrenia 22.65 11.74 8 80810 103 50524203
Chills 22.50 11.74 79 80739 96608 50427698
Dependent personality disorder 22.48 11.74 7 80811 59 50524247
Cardio-respiratory arrest 22.28 11.74 155 80663 53737 50470569
Speech disorder 22.27 11.74 114 80704 35434 50488872
Autonomic nervous system imbalance 22.17 11.74 23 80795 2362 50521944
Floppy iris syndrome 22.04 11.74 8 80810 112 50524194
Product administered to patient of inappropriate age 22.03 11.74 24 80794 2606 50521700
No adverse event 21.96 11.74 109 80709 33469 50490837
Intention tremor 21.93 11.74 11 80807 353 50523953
Loss of consciousness 21.90 11.74 259 80559 104094 50420212
Pulmonary fibrosis 21.80 11.74 6 80812 24431 50499875
Weight decreased 21.77 11.74 237 80581 221008 50303298
Shoplifting 21.77 11.74 4 80814 0 50524306
Sternal fracture 21.73 11.74 21 80797 1981 50522325
Cerebral haemorrhage 21.72 11.74 8 80810 27044 50497262
Hallucination, visual 21.68 11.74 67 80751 16515 50507791
Drug effective for unapproved indication 21.66 11.74 21 80797 1988 50522318
Urinary tract infection 21.64 11.74 241 80577 223779 50300527
Retinal coloboma 21.62 11.74 6 80812 32 50524274
Dysphoria 21.53 11.74 32 80786 4742 50519564
Localised infection 21.39 11.74 7 80811 25478 50498828
Food craving 21.35 11.74 18 80800 1421 50522885
Intentional product use issue 21.34 11.74 58 80760 76860 50447446
Anterograde amnesia 21.27 11.74 12 80806 490 50523816
Bladder dilatation 21.15 11.74 14 80804 764 50523542
Post-traumatic stress disorder 21.09 11.74 30 80788 4273 50520033
Influenza 20.94 11.74 73 80745 89465 50434841
Decreased activity 20.90 11.74 33 80785 5154 50519152
Full blood count decreased 20.87 11.74 5 80813 22341 50501965
Water intoxication 20.79 11.74 11 80807 395 50523911
Blood creatinine increased 20.70 11.74 58 80760 76102 50448204
Anaphylactic reaction 20.66 11.74 34 80784 54021 50470285
Fluid replacement 20.62 11.74 6 80812 39 50524267
Blood prolactin decreased 20.49 11.74 6 80812 40 50524266
Emotional poverty 20.46 11.74 10 80808 303 50524003
Polyuria 20.44 11.74 39 80779 7082 50517224
Abortion threatened 20.40 11.74 12 80806 531 50523775
Dehydration 20.39 11.74 151 80667 152298 50372008
Iris coloboma 20.36 11.74 6 80812 41 50524265
Premature baby 20.30 11.74 70 80748 18267 50506039
Hip fracture 20.27 11.74 8 80810 25923 50498383
Protrusion tongue 20.25 11.74 10 80808 310 50523996
Pneumonitis 20.13 11.74 11 80807 29499 50494807
COVID-19 20.12 11.74 27 80791 46635 50477671
Meningitis streptococcal 20.10 11.74 8 80810 146 50524160
Chest pain 20.10 11.74 183 80635 176699 50347607
Oromandibular dystonia 19.96 11.74 11 80807 429 50523877
Hunger 19.84 11.74 29 80789 4234 50520072
Metastases to liver 19.78 11.74 4 80814 20100 50504206
Hypoxia 19.69 11.74 32 80786 51091 50473215
Decreased interest 19.62 11.74 24 80794 2952 50521354
Selective eating disorder 19.47 11.74 19 80799 1813 50522493
Fear of weight gain 19.19 11.74 5 80813 20 50524286
Asocial behaviour 19.00 11.74 5 80813 21 50524285
Diabetic hyperosmolar coma 18.90 11.74 10 80808 359 50523947
Chest discomfort 18.85 11.74 80 80738 92642 50431664
Sleep deficit 18.84 11.74 11 80807 480 50523826
Electrocardiogram QRS complex prolonged 18.83 11.74 32 80786 5312 50518994
Refusal of treatment by patient 18.80 11.74 31 80787 5022 50519284
Twin pregnancy 18.77 11.74 15 80803 1098 50523208
Genitourinary symptom 18.73 11.74 6 80812 56 50524250
Akinesia 18.72 11.74 17 80801 1482 50522824
Polydipsia 18.69 11.74 24 80794 3100 50521206
Basal cell carcinoma 18.59 11.74 7 80811 23349 50500957
Obsessive thoughts 18.47 11.74 11 80807 498 50523808
Suicide threat 18.46 11.74 5 80813 24 50524282
Cellulitis 18.45 11.74 55 80763 70743 50453563
Cross sensitivity reaction 18.32 11.74 19 80799 1950 50522356
Right ventricular systolic pressure decreased 18.29 11.74 5 80813 25 50524281
Dyskinesia oesophageal 18.11 11.74 4 80814 6 50524300
Joint hyperextension 18.02 11.74 9 80809 286 50524020
Malaise 17.85 11.74 404 80414 335128 50189178
Pulmonary mass 17.83 11.74 4 80814 18701 50505605
Hyperkalaemia 17.69 11.74 31 80787 48058 50476248
Congenital ureteric anomaly 17.68 11.74 6 80812 68 50524238
Drowning 17.62 11.74 10 80808 413 50523893
Gastritis 17.62 11.74 16 80802 32967 50491339
Joint range of motion decreased 17.57 11.74 4 80814 18508 50505798
Emotional disorder 17.55 11.74 50 80768 11786 50512520
Myocarditis septic 17.53 11.74 5 80813 30 50524276
Renal impairment 17.48 11.74 62 80756 75599 50448707
Dyslipidaemia 17.44 11.74 33 80785 5955 50518351
Vision blurred 17.30 11.74 197 80621 78450 50445856
Homeless 17.30 11.74 6 80812 73 50524233
Blood pressure fluctuation 17.28 11.74 19 80799 35804 50488502
Non-cardiogenic pulmonary oedema 17.13 11.74 11 80807 570 50523736
Suspiciousness 17.02 11.74 9 80809 323 50523983
Nasal congestion 17.01 11.74 35 80783 51085 50473221
Syringe issue 16.98 11.74 19 80799 2125 50522181
Refusal of examination 16.87 11.74 6 80812 79 50524227
Metastases to bone 16.86 11.74 4 80814 17991 50506315
Developmental hip dysplasia 16.83 11.74 15 80803 1276 50523030
Ventricular septal defect 16.69 11.74 26 80792 4015 50520291
Haematocrit increased 16.51 11.74 18 80800 1956 50522350
Bone marrow failure 16.50 11.74 12 80806 27612 50496694
Screaming 16.45 11.74 22 80796 2956 50521350
Haemorrhoids 16.40 11.74 5 80813 19048 50505258
Transient aphasia 16.40 11.74 5 80813 39 50524267
Hypertonic bladder 16.33 11.74 22 80796 2978 50521328
Disruptive mood dysregulation disorder 16.32 11.74 3 80815 0 50524306
Noninfective encephalomyelitis 16.32 11.74 3 80815 0 50524306
Pyromania 16.32 11.74 3 80815 0 50524306
Hypoprolactinaemia 16.24 11.74 4 80814 12 50524294
Confusional arousal 16.22 11.74 6 80812 89 50524217
Eosinophilic myocarditis 16.22 11.74 9 80809 356 50523950
Hypernatraemia 16.19 11.74 33 80785 6288 50518018
Feeling of despair 16.19 11.74 18 80800 2000 50522306
Confusional state 16.18 11.74 400 80418 185528 50338778
Inappropriate antidiuretic hormone secretion 16.17 11.74 52 80766 13091 50511215
Negativism 16.10 11.74 9 80809 361 50523945
Helplessness 16.02 11.74 8 80810 254 50524052
Injection site haemorrhage 16.01 11.74 7 80811 21339 50502967
Bone disorder 16.00 11.74 5 80813 18747 50505559
Rectal haemorrhage 15.94 11.74 23 80795 38535 50485771
Trisomy 21 15.90 11.74 9 80809 370 50523936
Body mass index decreased 15.88 11.74 9 80809 371 50523935
Acute myocardial infarction 15.88 11.74 14 80804 29259 50495047
Cardiac failure 15.83 11.74 65 80753 75975 50448331
Rhinorrhoea 15.78 11.74 37 80781 51546 50472760
International normalised ratio increased 15.71 11.74 28 80790 43124 50481182
Breast enlargement 15.65 11.74 15 80803 1400 50522906
Delusion of reference 15.63 11.74 6 80812 99 50524207
Intermenstrual bleeding 15.62 11.74 34 80784 6780 50517526
Hypocalcaemia 15.57 11.74 12 80806 26804 50497502
Full blood count abnormal 15.55 11.74 9 80809 23379 50500927
Neutrophil count increased 15.55 11.74 54 80764 14141 50510165
Haematuria 15.46 11.74 11 80807 25602 50498704
Haematochezia 15.32 11.74 25 80793 39857 50484449
Negative thoughts 15.31 11.74 12 80806 854 50523452
Drug ineffective for unapproved indication 15.30 11.74 71 80747 21210 50503096
Asthma 15.28 11.74 82 80736 89255 50435051
Cataract 15.22 11.74 33 80785 47267 50477039
Antipsychotic drug level below therapeutic 15.18 11.74 8 80810 285 50524021
Injection site bruising 15.13 11.74 22 80796 36746 50487560
Grimacing 15.02 11.74 9 80809 412 50523894
Patient dissatisfaction with treatment 14.95 11.74 5 80813 54 50524252
Night sweats 14.91 11.74 19 80799 33555 50490751
Pseudomyopia 14.87 11.74 5 80813 55 50524251
Hypersomnia 14.86 11.74 56 80762 15258 50509048
Arachnoid cyst 14.83 11.74 7 80811 196 50524110
Muscle tightness 14.83 11.74 43 80775 10237 50514069
Affective ambivalence 14.80 11.74 4 80814 19 50524287
Gait disturbance 14.67 11.74 328 80490 149677 50374629
Trichotillomania 14.57 11.74 6 80812 120 50524186
Gastrointestinal lymphoma 14.55 11.74 5 80813 59 50524247
Urate nephropathy 14.53 11.74 6 80812 121 50524185
Immunodeficiency 14.49 11.74 3 80815 14825 50509481
Dyspepsia 14.41 11.74 65 80753 74032 50450274
Sleep-related eating disorder 14.36 11.74 11 80807 757 50523549
Dissociation 14.34 11.74 18 80800 2273 50522033
Electroconvulsive therapy 14.33 11.74 5 80813 62 50524244
Epilepsy 14.09 11.74 70 80748 21497 50502809
Interstitial lung disease 14.08 11.74 41 80777 53135 50471171
Pseudodementia 14.05 11.74 5 80813 66 50524240
Multiple fractures 14.04 11.74 32 80786 6579 50517727
Congenital hypothyroidism 13.97 11.74 7 80811 224 50524082
Convulsive threshold lowered 13.96 11.74 8 80810 337 50523969
Ataxia 13.86 11.74 51 80767 13735 50510571
Oral herpes 13.74 11.74 8 80810 20717 50503589
Osteopenia 13.72 11.74 5 80813 17013 50507293
Nodule 13.70 11.74 5 80813 16998 50507308
Obstructive airways disorder 13.67 11.74 4 80814 15648 50508658
Cast application 13.62 11.74 4 80814 27 50524279
Dysbiosis 13.55 11.74 10 80808 650 50523656
Delusional disorder, erotomanic type 13.49 11.74 4 80814 28 50524278
Abnormal weight gain 13.49 11.74 14 80804 1438 50522868
Gestational hypertension 13.48 11.74 17 80801 2156 50522150
Lung neoplasm malignant 13.44 11.74 4 80814 15480 50508826
Hyperreflexia 13.44 11.74 27 80791 5091 50519215
Breath odour 13.37 11.74 13 80805 1235 50523071
Schizophreniform disorder 13.34 11.74 5 80813 77 50524229
Foot deformity 13.34 11.74 7 80811 19203 50505103
Rash pruritic 13.33 11.74 36 80782 47810 50476496
Abnormal dreams 13.31 11.74 39 80779 9338 50514968
Pneumonia aspiration 13.30 11.74 90 80728 30914 50493392
Menstruation irregular 13.28 11.74 30 80788 6132 50518174
Spasmodic dysphonia 13.23 11.74 5 80813 79 50524227
Osteonecrosis 13.17 11.74 10 80808 22507 50501799
Diabetic coma 13.04 11.74 10 80808 689 50523617
Hypersomnia-bulimia syndrome 13.04 11.74 3 80815 6 50524300
Embolism venous 12.96 11.74 18 80800 2507 50521799
Anhedonia 12.94 11.74 39 80779 9485 50514821
Hemiparesis 12.93 11.74 8 80810 20040 50504266
Pregnancy with implant contraceptive 12.83 11.74 16 80802 2007 50522299
Type 1 diabetes mellitus 12.81 11.74 20 80798 3093 50521213
Panic attack 12.80 11.74 63 80755 19279 50505027
Intrapartum haemorrhage 12.72 11.74 3 80815 7 50524299
Taciturnity 12.72 11.74 3 80815 7 50524299
Laboratory test abnormal 12.71 11.74 11 80807 23197 50501109
Hypotonia 12.68 11.74 35 80783 8099 50516207
Induced labour 12.68 11.74 11 80807 903 50523403
Adverse event 12.68 11.74 116 80702 43647 50480659
Menstrual disorder 12.62 11.74 24 80794 4346 50519960
Unevaluable event 12.58 11.74 35 80783 46031 50478275
Axonal neuropathy 12.57 11.74 11 80807 913 50523393
Ear pain 12.57 11.74 16 80802 28267 50496039
Hot flush 12.48 11.74 33 80785 44136 50480170
Pulmonary embolism 12.46 11.74 230 80588 101474 50422832
Sluggishness 12.46 11.74 24 80794 4389 50519917
Device related infection 12.39 11.74 9 80809 20726 50503580
Diabetic ketoacidosis 12.39 11.74 59 80759 17813 50506493
Drug withdrawal syndrome neonatal 12.39 11.74 15 80803 1826 50522480
Foetal malnutrition 12.33 11.74 5 80813 96 50524210
Female sexual dysfunction 12.33 11.74 4 80814 39 50524267
Eosinophil count decreased 12.26 11.74 14 80804 1601 50522705
Fungal infection 12.26 11.74 18 80800 29947 50494359
Lung disorder 12.26 11.74 34 80784 44765 50479541
Neonatal respiratory distress 12.25 11.74 7 80811 293 50524013
Swelling face 12.22 11.74 43 80775 52552 50471754
Blood folate decreased 12.21 11.74 9 80809 584 50523722
Chronic obstructive pulmonary disease 12.20 11.74 44 80774 53391 50470915
Merycism 12.18 11.74 6 80812 185 50524121
Hyponatriuria 12.18 11.74 3 80815 9 50524297
Emotional distress 12.18 11.74 83 80735 28580 50495726
Biliary tract infection 12.16 11.74 8 80810 432 50523874
Mydriasis 12.14 11.74 41 80777 10586 50513720
Scar excision 12.06 11.74 4 80814 42 50524264
Cholangitis infective 11.95 11.74 6 80812 193 50524113
Subdural haematoma 11.89 11.74 3 80815 12944 50511362
Abdominal distension 11.88 11.74 68 80750 72835 50451471
Foetal growth restriction 11.84 11.74 30 80788 6597 50517709
Transient tachypnoea of the newborn 11.83 11.74 5 80813 107 50524199
Adrenal insufficiency 11.80 11.74 4 80814 14239 50510067

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 1164.45 13.58 456 58728 6286 29509057
Neuroleptic malignant syndrome 1129.61 13.58 580 58604 15568 29499775
Psychotic disorder 1003.69 13.58 580 58604 19774 29495569
Tardive dyskinesia 881.04 13.58 348 58836 4910 29510433
Dystonia 757.05 13.58 376 58808 9373 29505970
Extrapyramidal disorder 739.71 13.58 383 58801 10448 29504895
Sedation 681.83 13.58 428 58756 16977 29498366
Delusion 561.51 13.58 323 58861 10893 29504450
Weight increased 555.54 13.58 724 58460 75943 29439400
Parkinsonism 513.09 13.58 263 58921 7015 29508328
Suicide attempt 502.58 13.58 468 58716 33642 29481701
Hallucination, auditory 450.32 13.58 265 58919 9328 29506015
Schizophrenia 447.67 13.58 232 58952 6333 29509010
Dyskinesia 425.15 13.58 339 58845 19722 29495621
Aggression 412.33 13.58 428 58756 35113 29480230
Suicidal ideation 409.84 13.58 422 58762 34294 29481049
Gambling disorder 360.55 13.58 131 59053 1444 29513899
Product use in unapproved indication 351.58 13.58 626 58558 86249 29429094
Mania 309.17 13.58 201 58983 8462 29506881
Agitation 288.02 13.58 429 58755 50875 29464468
Obsessive-compulsive disorder 287.16 13.58 153 59031 4423 29510920
Treatment noncompliance 286.70 13.58 295 58889 23932 29491411
Sexual dysfunction 260.76 13.58 156 59028 5658 29509685
Blood creatine phosphokinase increased 247.12 13.58 353 58831 40291 29475052
Blood prolactin abnormal 244.36 13.58 84 59100 776 29514567
Catatonia 243.27 13.58 136 59048 4332 29511011
Restlessness 242.97 13.58 259 58925 21886 29493457
Salivary hypersecretion 240.38 13.58 162 59022 7247 29508096
Psychotic symptom 234.70 13.58 93 59091 1321 29514022
Hyperprolactinaemia 215.94 13.58 85 59099 1185 29514158
Muscle rigidity 203.48 13.58 161 59023 9250 29506093
Abnormal behaviour 196.69 13.58 237 58947 22890 29492453
Irritability 196.61 13.58 232 58952 21920 29493423
Febrile neutropenia 193.73 13.58 7 59177 112233 29403110
Diarrhoea 189.75 13.58 233 58951 332465 29182878
Antipsychotic drug level below therapeutic 182.93 13.58 86 59098 1888 29513455
Priapism 182.22 13.58 113 59071 4375 29510968
Pneumonia 181.73 13.58 225 58959 319947 29195396
Anaemia 181.27 13.58 88 59096 200863 29314480
Dyspnoea 178.84 13.58 236 58948 326496 29188847
Anosognosia 172.30 13.58 64 59120 754 29514589
Paranoia 165.85 13.58 146 59038 9731 29505612
Disinhibition 163.09 13.58 87 59097 2520 29512823
Oculogyric crisis 160.02 13.58 70 59114 1291 29514052
Psychiatric decompensation 159.64 13.58 72 59112 1432 29513911
Social avoidant behaviour 158.65 13.58 89 59095 2853 29512490
Somnolence 157.68 13.58 479 58705 93476 29421867
Anxiety 155.41 13.58 448 58736 84917 29430426
Increased appetite 153.59 13.58 114 59070 5950 29509393
Persecutory delusion 152.66 13.58 78 59106 2063 29513280
Psychiatric symptom 152.10 13.58 89 59095 3095 29512248
Tremor 149.69 13.58 402 58782 73136 29442207
Emotional poverty 145.77 13.58 49 59135 420 29514923
Foetal exposure during pregnancy 141.77 13.58 248 58936 33619 29481724
Hypersexuality 141.02 13.58 64 59120 1292 29514051
Apathy 140.80 13.58 109 59075 6062 29509281
Metabolic disorder 139.88 13.58 89 59095 3606 29511737
Drug ineffective 138.71 13.58 1216 57968 361954 29153389
Disturbance in social behaviour 136.04 13.58 67 59117 1635 29513708
Obesity 134.89 13.58 130 59054 9733 29505610
Euphoric mood 131.92 13.58 95 59089 4730 29510613
Intentional self-injury 126.59 13.58 140 59044 12321 29503022
Prescribed overdose 125.50 13.58 118 59066 8565 29506778
Psychomotor hyperactivity 125.25 13.58 115 59069 8098 29507245
Thinking abnormal 124.97 13.58 95 59089 5141 29510202
Malignant neoplasm progression 122.75 13.58 6 59178 73853 29441490
Serotonin syndrome 122.74 13.58 163 59021 17349 29497994
Mental impairment 122.22 13.58 119 59065 9022 29506321
Therapeutic product effect variable 121.26 13.58 64 59120 1813 29513530
Acute kidney injury 119.67 13.58 218 58966 265049 29250294
Tic 114.12 13.58 61 59123 1774 29513569
Bruxism 113.68 13.58 58 59126 1529 29513814
Drooling 109.98 13.58 71 59113 2950 29512393
Disease progression 104.16 13.58 19 59165 81897 29433446
Arthralgia 103.51 13.58 77 59107 139540 29375803
Compulsive sexual behaviour 103.12 13.58 32 59152 206 29515137
Insomnia 101.13 13.58 398 58786 88363 29426980
Cough 100.42 13.58 65 59119 126662 29388681
Homicidal ideation 98.55 13.58 62 59122 2462 29512881
Hallucination 94.51 13.58 248 58936 44464 29470879
Cogwheel rigidity 93.63 13.58 47 59137 1196 29514147
Prescribed underdose 92.38 13.58 95 59089 7691 29507652
Hospitalisation 91.08 13.58 249 58935 45739 29469604
Schizoaffective disorder 90.31 13.58 44 59140 1048 29514295
Off label use 89.72 13.58 957 58227 299843 29215500
Sepsis 88.52 13.58 93 59091 142589 29372754
Libido increased 87.75 13.58 38 59146 683 29514660
Oppositional defiant disorder 84.90 13.58 34 59150 497 29514846
Torticollis 84.24 13.58 42 59142 1053 29514290
Death 84.08 13.58 376 58808 341708 29173635
Loss of libido 83.68 13.58 54 59130 2242 29513101
Intentional overdose 82.75 13.58 215 58969 38313 29477030
Affective disorder 81.93 13.58 60 59124 3066 29512277
Pain 81.59 13.58 136 59048 171296 29344047
Hypotension 81.17 13.58 167 59017 194187 29321156
Electrocardiogram QT prolonged 81.07 13.58 205 58979 35932 29479411
Delusional disorder, persecutory type 80.98 13.58 27 59157 225 29515118
Compulsive shopping 79.96 13.58 30 59154 364 29514979
Myocarditis 79.89 13.58 104 59080 10852 29504491
Trismus 79.63 13.58 53 59131 2320 29513023
Asthenia 79.32 13.58 198 58986 215052 29300291
Blood prolactin increased 78.91 13.58 45 59139 1489 29513854
Hypomania 78.89 13.58 51 59133 2124 29513219
Pyrexia 78.80 13.58 303 58881 287319 29228024
Economic problem 78.67 13.58 42 59142 1218 29514125
General physical health deterioration 77.13 13.58 56 59128 102801 29412542
Gambling 75.01 13.58 24 59160 173 29515170
Drug monitoring procedure incorrectly performed 74.81 13.58 25 59159 210 29515133
Drug interaction 74.41 13.58 660 58524 196725 29318618
Anger 74.20 13.58 100 59084 10790 29504553
Atrial fibrillation 73.55 13.58 62 59122 105584 29409759
Pleural effusion 73.53 13.58 26 59158 71882 29443461
Gastrointestinal haemorrhage 72.81 13.58 34 59150 79499 29435844
Pruritus 72.63 13.58 76 59108 116773 29398570
Sedation complication 72.45 13.58 40 59144 1242 29514101
Mental disorder 72.41 13.58 108 59076 12797 29502546
Interstitial lung disease 72.05 13.58 14 59170 57704 29457639
Neuropathy peripheral 70.40 13.58 27 59157 71000 29444343
Infection 69.97 13.58 33 59151 76718 29438625
Product administered to patient of inappropriate age 69.68 13.58 51 59133 2604 29512739
Renal failure 69.47 13.58 81 59103 118518 29396825
Thrombocytopenia 68.83 13.58 102 59082 134721 29380622
Pain in extremity 68.44 13.58 72 59112 110361 29404982
International normalised ratio increased 66.69 13.58 6 59178 44366 29470977
Joint swelling 66.43 13.58 10 59174 49620 29465723
Oedema peripheral 65.89 13.58 66 59118 103491 29411852
Breech presentation 64.95 13.58 20 59164 125 29515218
Sleep disorder 63.98 13.58 147 59037 24239 29491104
Hyperkalaemia 63.10 13.58 22 59162 61370 29453973
Abdominal pain 62.87 13.58 109 59075 135248 29380095
Overdose 62.29 13.58 320 58864 79499 29435844
Nausea 62.25 13.58 333 58851 288922 29226421
Depression 62.09 13.58 335 58849 84812 29430531
Cardiac failure congestive 60.99 13.58 39 59145 76542 29438801
Antipsychotic drug level increased 60.65 13.58 51 59133 3192 29512151
Underdose 60.49 13.58 95 59089 11774 29503569
Decreased eye contact 60.46 13.58 26 59158 459 29514884
Rhabdomyolysis 59.25 13.58 260 58924 60548 29454795
Speech disorder 58.68 13.58 139 59045 23377 29491966
Plasma cell myeloma 58.63 13.58 4 59180 37111 29478232
Muscle twitching 58.22 13.58 76 59108 7950 29507393
Victim of child abuse 57.97 13.58 30 59154 815 29514528
Keratoconus 57.84 13.58 16 59168 64 29515279
Ascites 57.69 13.58 4 59180 36615 29478728
Personality change 57.58 13.58 58 59126 4580 29510763
Fatigue 56.00 13.58 388 58796 316433 29198910
Myocardial infarction 55.73 13.58 84 59100 110212 29405131
Coronary artery disease 54.56 13.58 11 59173 44179 29471164
Homosexuality 53.70 13.58 14 59170 42 29515301
Blood triglycerides increased 52.39 13.58 93 59091 12741 29502602
Sudden death 52.22 13.58 98 59086 14012 29501331
Infusion related reaction 51.99 13.58 12 59172 43874 29471469
Refusal of treatment by patient 51.61 13.58 55 59129 4639 29510704
Water intoxication 51.23 13.58 22 59162 387 29514956
Dystonic tremor 51.18 13.58 18 59166 179 29515164
Septic shock 51.00 13.58 31 59153 62529 29452814
Blood prolactin decreased 50.46 13.58 19 59165 233 29515110
Tachycardia 50.16 13.58 281 58903 72129 29443214
Haemoglobin decreased 49.64 13.58 88 59096 108287 29407056
Respiratory failure 49.04 13.58 74 59110 97057 29418286
Affect lability 48.71 13.58 46 59138 3356 29511987
Mucosal inflammation 48.22 13.58 4 59180 31591 29483752
Bradykinesia 48.19 13.58 46 59138 3401 29511942
Back pain 46.89 13.58 83 59101 102201 29413142
Cardiac failure 46.56 13.58 54 59130 79233 29436110
Blepharospasm 46.50 13.58 28 59156 1027 29514316
Antipsychotic drug level decreased 46.07 13.58 26 59158 843 29514500
Exhibitionism 46.03 13.58 12 59172 36 29515307
Self-injurious ideation 45.77 13.58 32 59152 1519 29513824
Lactic acidosis 45.69 13.58 4 59180 30243 29485100
Diabetes mellitus 45.60 13.58 179 59005 39652 29475691
Dysarthria 44.79 13.58 150 59034 30761 29484582
Paraphilia 44.01 13.58 13 59171 69 29515274
Delusion of grandeur 43.92 13.58 20 59164 407 29514936
Hypoxia 43.74 13.58 20 59164 47359 29467984
Therapeutic product effect incomplete 43.68 13.58 175 59009 39130 29476213
Impulsive behaviour 43.62 13.58 34 59150 1909 29513434
Disturbance in attention 43.38 13.58 117 59067 21307 29494036
Wrong technique in product usage process 43.34 13.58 150 59034 31278 29484065
Pancytopenia 43.30 13.58 62 59122 83106 29432237
Depressive symptom 42.85 13.58 32 59152 1685 29513658
Melaena 42.37 13.58 6 59178 31170 29484173
Oromandibular dystonia 42.00 13.58 20 59164 452 29514891
Haematuria 41.74 13.58 18 59166 44121 29471222
Abdominal distension 41.43 13.58 20 59164 45891 29469452
Antidepressant drug level above therapeutic 41.22 13.58 15 59169 166 29515177
Musculoskeletal stiffness 41.01 13.58 166 59018 37292 29478051
Acute myocardial infarction 40.89 13.58 23 59161 48415 29466928
Musculoskeletal pain 40.71 13.58 5 59179 28948 29486395
Urticaria 40.63 13.58 30 59154 54630 29460713
Hypothermia 40.38 13.58 69 59115 9170 29506173
Tongue movement disturbance 39.53 13.58 12 59172 71 29515272
Hostility 39.45 13.58 23 59161 794 29514549
Hyperthermia 39.35 13.58 69 59115 9361 29505982
Pleurothotonus 39.28 13.58 25 59159 1013 29514330
Bankruptcy 38.93 13.58 9 59175 13 29515330
Mood altered 38.69 13.58 63 59121 8048 29507295
Haematochezia 38.43 13.58 13 59171 36970 29478373
Loss of employment 38.41 13.58 19 59165 468 29514875
Multiple organ dysfunction syndrome 38.12 13.58 42 59142 63074 29452269
Nasopharyngitis 37.95 13.58 38 59146 59627 29455716
Crying 37.77 13.58 50 59134 5301 29510042
Rheumatoid arthritis 37.67 13.58 9 59175 32143 29483200
Chronic kidney disease 37.50 13.58 13 59171 36403 29478940
Dyslipidaemia 37.30 13.58 53 59131 6008 29509335
Heat stroke 37.18 13.58 23 59161 886 29514457
Mydriasis 37.14 13.58 53 59131 6032 29509311
Psychosexual disorder 36.98 13.58 12 59172 91 29515252
No adverse event 36.95 13.58 97 59087 17381 29497962
Acute psychosis 36.75 13.58 29 59155 1658 29513685
Completed suicide 36.62 13.58 307 58877 89939 29425404
Psychomotor retardation 36.55 13.58 37 59147 2939 29512404
Bronchitis 36.54 13.58 14 59170 36854 29478489
Urinary incontinence 36.42 13.58 93 59091 16388 29498955
Electrocardiogram QT shortened 36.38 13.58 13 59171 136 29515207
Exposure via breast milk 36.37 13.58 29 59155 1683 29513660
Epistaxis 36.37 13.58 30 59154 51674 29463669
Chills 36.28 13.58 54 59130 71246 29444097
Feeling guilty 36.14 13.58 16 59168 304 29515039
Analgesic drug level above therapeutic 36.06 13.58 15 59169 243 29515100
Dyspnoea exertional 35.93 13.58 14 59170 36476 29478867
Metabolic syndrome 35.75 13.58 27 59157 1446 29513897
Rash 35.67 13.58 228 58956 189591 29325752
Stomatitis 35.31 13.58 15 59169 37098 29478245
Haemoptysis 34.92 13.58 9 59175 30541 29484802
Premature baby 34.61 13.58 94 59090 17186 29498157
Rectal haemorrhage 34.44 13.58 13 59171 34536 29480807
Colitis 34.23 13.58 10 59174 31238 29484105
Withdrawal syndrome 34.21 13.58 71 59113 10921 29504422
Disturbance in sexual arousal 34.15 13.58 12 59172 119 29515224
Sinusitis 34.12 13.58 13 59171 34337 29481006
Insurance issue 33.88 13.58 22 59162 923 29514420
Renal impairment 33.77 13.58 70 59114 81263 29434080
Paradoxical drug reaction 33.52 13.58 34 59150 2707 29512636
Hiccups 33.40 13.58 62 59122 8791 29506552
Enuresis 33.37 13.58 30 59154 2054 29513289
Erythema 33.17 13.58 63 59121 75543 29439800
Posture abnormal 33.11 13.58 29 59155 1918 29513425
Blood creatinine increased 33.06 13.58 76 59108 85026 29430317
Decreased appetite 33.03 13.58 164 59020 145178 29370165
Urinary tract infection 32.89 13.58 59 59125 72295 29443048
Staring 32.86 13.58 25 59159 1354 29513989
Delirium 32.85 13.58 161 59023 39236 29476107
Cerebral haemorrhage 32.73 13.58 11 59173 31415 29483928
Haematoma 32.66 13.58 4 59180 23208 29492135
Foetal disorder 32.50 13.58 20 59164 763 29514580
Bradyphrenia 32.28 13.58 41 59143 4173 29511170
Intentional product use issue 32.00 13.58 23 59161 42475 29472868
Haemorrhage 31.89 13.58 26 59158 45046 29470297
Schizophreniform disorder 31.88 13.58 10 59174 67 29515276
Depressed mood 31.48 13.58 88 59096 16360 29498983
Type 2 diabetes mellitus 31.44 13.58 78 59106 13503 29501840
Basilar artery occlusion 31.38 13.58 10 59174 71 29515272
Sleep-related eating disorder 31.33 13.58 14 59170 272 29515071
Maternal exposure during breast feeding 31.20 13.58 25 59159 1461 29513882
Head titubation 31.10 13.58 14 59170 277 29515066
Depressed level of consciousness 30.82 13.58 151 59033 36791 29478552
Wheezing 30.73 13.58 14 59170 33226 29482117
Hyperphagia 30.70 13.58 23 59161 1217 29514126
Pneumonitis 30.67 13.58 9 59175 28035 29487308
Antisocial behaviour 30.30 13.58 14 59170 295 29515048
Blunted affect 30.17 13.58 14 59170 298 29515045
Choreoathetosis 30.00 13.58 21 59163 999 29514344
Galactorrhoea 29.98 13.58 15 59169 379 29514964
Eye movement disorder 29.97 13.58 37 59147 3659 29511684
Peripheral swelling 29.85 13.58 51 59133 63688 29451655
Patient restraint 29.82 13.58 10 59174 85 29515258
Social problem 29.80 13.58 19 59165 772 29514571
Product substitution issue 29.44 13.58 60 59124 9112 29506231
Blood cholesterol increased 29.42 13.58 83 59101 15512 29499831
Leukopenia 29.25 13.58 200 58984 55003 29460340
Drug hypersensitivity 29.14 13.58 58 59126 68348 29446995
Gynaecomastia 29.08 13.58 56 59128 8161 29507182
Sopor 28.76 13.58 66 59118 10868 29504475
Polydipsia 28.60 13.58 35 59149 3430 29511913
Prostate cancer 28.27 13.58 8 59176 25519 29489824
Inability to afford medication 28.19 13.58 20 59164 972 29514371
Multiple drug therapy 28.00 13.58 14 59170 353 29514990
Accommodation disorder 28 13.58 12 59172 210 29515133
High-grade B-cell lymphoma 27.88 13.58 9 59175 67 29515276
Neutropenia neonatal 27.83 13.58 17 59167 640 29514703
Poor quality sleep 27.72 13.58 51 59133 7182 29508161
Diabetic coma 27.58 13.58 18 59166 762 29514581
Hyperkinesia 27.56 13.58 24 59160 1575 29513768
Dysphoria 27.52 13.58 27 59157 2065 29513278
Delusional disorder, unspecified type 27.36 13.58 17 59167 660 29514683
Soliloquy 27.20 13.58 14 59170 376 29514967
Blood thyroid stimulating hormone decreased 27.06 13.58 25 59159 1773 29513570
Coordination abnormal 27.06 13.58 50 59134 7064 29508279
Headache 26.88 13.58 221 58963 173786 29341557
Bipolar disorder 26.74 13.58 33 59151 3262 29512081
Reduced facial expression 26.70 13.58 17 59167 689 29514654
Neoplasm progression 26.70 13.58 3 59181 18609 29496734
Epidural lipomatosis 26.59 13.58 17 59167 694 29514649
Coma 26.57 13.58 152 59032 39298 29476045
Granulocytopenia 26.50 13.58 45 59139 5949 29509394
Red cell distribution width decreased 26.28 13.58 11 59173 181 29515162
Hyperreflexia 26.19 13.58 30 59154 2742 29512601
Hypokinesia 26.14 13.58 51 59133 7503 29507840
Movement disorder 26.06 13.58 61 59123 10176 29505167
Pyramidal tract syndrome 25.96 13.58 11 59173 187 29515156
Herpes zoster 25.75 13.58 14 59170 30038 29485305
Neutrophil count increased 25.44 13.58 76 59108 14666 29500677
Swelling 25.40 13.58 20 59164 35263 29480080
Hyperhidrosis 25.34 13.58 218 58966 64322 29451021
Stereotypy 25.26 13.58 16 59168 643 29514700
Chest discomfort 25.21 13.58 33 59151 45950 29469393
Myelodysplastic syndrome 25.20 13.58 3 59181 17791 29497552
Blood glucose increased 25.17 13.58 203 58981 58781 29456562
Mood swings 25.15 13.58 49 59135 7202 29508141
Altered state of consciousness 24.91 13.58 92 59092 19797 29495546
Orthostatic hypertension 24.84 13.58 11 59173 209 29515134
Cholestasis 24.81 13.58 8 59176 23454 29491889
Stupor 24.76 13.58 29 59155 2715 29512628
Adverse event 24.67 13.58 77 59107 15214 29500129
Physical assault 24.40 13.58 19 59165 1065 29514278
Cerebrovascular accident 24.34 13.58 76 59108 76835 29438508
Seizure 24.25 13.58 289 58895 92834 29422509
Imprisonment 24.20 13.58 14 59170 476 29514867
Antipsychotic drug level above therapeutic 24.14 13.58 19 59165 1082 29514261
Muscle contractions involuntary 24.05 13.58 23 59161 1704 29513639
Cellulitis 24.02 13.58 34 59150 45806 29469537
Restless legs syndrome 23.99 13.58 47 59137 6937 29508406
Pneumonia aspiration 23.73 13.58 140 59044 36597 29478746
Tongue biting 23.70 13.58 16 59168 717 29514626
Obsessive thoughts 23.58 13.58 15 59169 607 29514736
Foetal distress syndrome 23.56 13.58 18 59166 981 29514362
Negative thoughts 23.47 13.58 15 59169 612 29514731
Gaze palsy 23.41 13.58 20 59164 1279 29514064
Homeless 23.27 13.58 6 59178 17 29515326
Compulsive hoarding 23.27 13.58 6 59178 17 29515326
Platelet count decreased 23.25 13.58 119 59065 104553 29410790
Staphylococcal infection 23.11 13.58 15 59169 29225 29486118
Fall 23.03 13.58 235 58949 176943 29338400
Feeling abnormal 23.02 13.58 187 58997 54258 29461085
Parkinsonian rest tremor 22.96 13.58 9 59175 124 29515219
Slow speech 22.70 13.58 17 59167 899 29514444
Type 1 diabetes mellitus 22.62 13.58 32 59152 3612 29511731
Eosinophilic myocarditis 22.47 13.58 13 59171 442 29514901
Excessive masturbation 22.44 13.58 8 59176 83 29515260
Hallucinations, mixed 22.43 13.58 26 59158 2407 29512936
Arthritis 22.41 13.58 11 59173 25008 29490335
Dysphagia 22.34 13.58 187 58997 54739 29460604
Cholelithiasis 22.32 13.58 5 59179 18667 29496676
Skin lesion 22.15 13.58 5 59179 18567 29496776
Nervousness 22.14 13.58 61 59123 11245 29504098
Anxiolytic therapy 22.10 13.58 6 59178 22 29515321
Dehydration 21.94 13.58 137 59047 114611 29400732
Inappropriate schedule of product administration 21.73 13.58 158 59026 44314 29471029
Dysphemia 21.51 13.58 20 59164 1430 29513913
Cataract 21.35 13.58 9 59175 22369 29492974
Muscle contracture 21.29 13.58 18 59166 1135 29514208
Rash maculo-papular 21.27 13.58 11 59173 24278 29491065
Sudden cardiac death 21.06 13.58 29 59155 3193 29512150
Influenza 21.02 13.58 32 59152 41849 29473494
Ejaculation delayed 20.96 13.58 10 59174 227 29515116
Energy increased 20.95 13.58 18 59166 1160 29514183
Skin ulcer 20.68 13.58 6 59178 18834 29496509
Renal hypertension 20.67 13.58 9 59175 164 29515179
Diverticulitis 20.65 13.58 5 59179 17699 29497644
Encephalopathy 20.63 13.58 19 59165 31024 29484319
Condition aggravated 20.63 13.58 409 58775 145886 29369457
Drug dependence 20.63 13.58 90 59094 20891 29494452
Ataxia 20.51 13.58 62 59122 12041 29503302
Drug therapy enhancement 20.44 13.58 6 59178 31 29515312
Upper respiratory tract infection 20.33 13.58 15 59169 27334 29488009
Dysgeusia 20.26 13.58 10 59174 22664 29492679
Oedema 20.26 13.58 31 59153 40452 29474891
Leukaemia 20.11 13.58 31 59153 3779 29511564
Dry skin 19.76 13.58 11 59173 23296 29492047
Chest pain 19.74 13.58 137 59047 111836 29403507
Autonomic nervous system imbalance 19.61 13.58 24 59160 2352 29512991
Subdural haematoma 19.60 13.58 6 59178 18187 29497156
Anamnestic reaction 19.55 13.58 6 59178 37 29515306
Diarrhoea infectious 19.54 13.58 12 59172 456 29514887
Myalgia 19.51 13.58 79 59105 73940 29441403
Abdominal pain upper 19.48 13.58 60 59124 60933 29454410
Tearfulness 19.47 13.58 20 59164 1616 29513727
Pneumothorax 19.43 13.58 4 59180 15838 29499505
Neurotoxicity 19.42 13.58 3 59181 14610 29500733
Gangrene neonatal 19.37 13.58 9 59175 192 29515151
Dyspepsia 19.36 13.58 19 59165 30106 29485237
Haemorrhage intracranial 19.29 13.58 3 59181 14539 29500804
Gout 19.29 13.58 5 59179 16906 29498437
Blood ketone body 19.27 13.58 7 59177 77 29515266
Autism spectrum disorder 19.21 13.58 22 59162 2010 29513333
Upper gastrointestinal haemorrhage 19.08 13.58 10 59174 21904 29493439
Hypoacusis 19.08 13.58 3 59181 14420 29500923
Respiratory depression 19.03 13.58 65 59119 13458 29501885
Ventricular septal defect 19.03 13.58 29 59155 3500 29511843
Diabetic ketoacidosis 19.01 13.58 73 59111 16000 29499343
Blood urea increased 18.93 13.58 17 59167 28095 29487248
Hunger 18.85 13.58 18 59166 1331 29514012
Fluid retention 18.74 13.58 12 59172 23548 29491795
Libido decreased 18.65 13.58 32 59152 4266 29511077
COVID-19 18.58 13.58 27 59157 35987 29479356
Benign ethnic neutropenia 18.55 13.58 6 59178 45 29515298
Gender dysphoria 18.55 13.58 6 59178 45 29515298
Suspiciousness 18.51 13.58 10 59174 297 29515046
Impulse-control disorder 18.37 13.58 17 59167 1208 29514135
Juvenile idiopathic arthritis 18.35 13.58 18 59166 1376 29513967
Troponin T increased 18.10 13.58 18 59166 1399 29513944
Flat affect 18.09 13.58 14 59170 778 29514565
Inappropriate affect 17.87 13.58 12 59172 533 29514810
Weight decrease neonatal 17.75 13.58 10 59174 323 29515020
Full blood count decreased 17.73 13.58 5 59179 15987 29499356
Drug effective for unapproved indication 17.70 13.58 18 59166 1437 29513906
Somatic hallucination 17.69 13.58 5 59179 22 29515321
Impaired self-care 17.66 13.58 15 59169 952 29514391
Underweight 17.57 13.58 11 59173 433 29514910
Rebound effect 17.55 13.58 21 59163 2010 29513333
Postictal psychosis 17.38 13.58 8 59176 167 29515176
Blood pressure systolic increased 17.36 13.58 6 59178 16839 29498504
Cloacal exstrophy 17.30 13.58 6 59178 57 29515286
Urinary retention 17.15 13.58 116 59068 31782 29483561
Tachyphrenia 17.10 13.58 16 59168 1153 29514190
Flatulence 17.09 13.58 7 59177 17702 29497641
Thrombosis 17.06 13.58 38 59146 43007 29472336
Hypokalaemia 17.04 13.58 48 59136 50155 29465188
Anaphylactic reaction 17.03 13.58 18 59166 27555 29487788
Vision blurred 16.98 13.58 138 59046 40038 29475305
Tension 16.90 13.58 20 59164 1893 29513450
Neuroleptic-induced deficit syndrome 16.85 13.58 5 59179 27 29515316
Suicidal behaviour 16.82 13.58 17 59167 1348 29513995
Renal tubular necrosis 16.78 13.58 4 59180 14311 29501032
Compulsions 16.75 13.58 8 59176 182 29515161
Constipation 16.70 13.58 147 59037 114013 29401330
Bone pain 16.70 13.58 8 59176 18444 29496899
Productive cough 16.56 13.58 23 59161 31236 29484107
Haematemesis 16.45 13.58 15 59169 24611 29490732
Candida infection 16.44 13.58 5 59179 15220 29500123
Drug abuse 16.23 13.58 237 58947 79646 29435697
Selective mutism 16.20 13.58 6 59178 70 29515273
Jaundice neonatal 16.13 13.58 16 59168 1240 29514103
Psychomotor skills impaired 15.98 13.58 23 59161 2638 29512705
Hypertonia 15.95 13.58 28 59156 3801 29511542
Divorced 15.87 13.58 4 59180 10 29515333
Arthropathy 15.79 13.58 12 59172 21542 29493801
Generalised anxiety disorder 15.79 13.58 12 59172 649 29514694
Floppy iris syndrome 15.78 13.58 9 59175 298 29515045
Osteomyelitis 15.74 13.58 4 59180 13705 29501638
Drug withdrawal syndrome neonatal 15.69 13.58 26 59158 3369 29511974
Complicated fracture 15.65 13.58 3 59181 0 29515343
Excessive sexual fantasies 15.65 13.58 3 59181 0 29515343
Ejaculation disorder 15.63 13.58 14 59170 954 29514389
Skin turgor decreased 15.58 13.58 10 59174 411 29514932
Ketosis 15.54 13.58 10 59174 413 29514930
Emotional distress 15.53 13.58 62 59122 13833 29501510
Grandiosity 15.38 13.58 9 59175 313 29515030
Muscular weakness 15.25 13.58 68 59116 61984 29453359
Angina pectoris 15.25 13.58 20 59164 27830 29487513
Peripheral artery thrombosis 15.24 13.58 20 59164 2102 29513241
Hypoglycaemia 15.13 13.58 48 59136 48298 29467045
Weight decreased 15.05 13.58 212 58972 150693 29364650
Foetal growth restriction 14.99 13.58 27 59157 3739 29511604
Gastrooesophageal reflux disease 14.92 13.58 25 59159 31471 29483872
Clostridium difficile colitis 14.89 13.58 4 59180 13208 29502135
Bacteraemia 14.89 13.58 7 59177 16316 29499027
Electrocardiogram abnormal 14.83 13.58 40 59144 7282 29508061
Chronic obstructive pulmonary disease 14.77 13.58 38 59146 40917 29474426
Hepatic steatosis 14.60 13.58 64 59120 14882 29500461
Erectile dysfunction 14.58 13.58 73 59111 17936 29497407
Anticholinergic syndrome 14.57 13.58 13 59171 881 29514462
Product reconstitution quality issue 14.55 13.58 6 59178 95 29515248
Bipolar I disorder 14.52 13.58 12 59172 733 29514610
Rash pruritic 14.49 13.58 14 59170 22349 29492994
Hallucination, visual 14.45 13.58 64 59120 14951 29500392
Moaning 14.43 13.58 12 59172 739 29514604
Poisoning deliberate 14.42 13.58 34 59150 5697 29509646
Ischaemic stroke 14.35 13.58 7 59177 15970 29499373
Sinus tachycardia 14.33 13.58 64 59120 15005 29500338
Neutropenic sepsis 14.30 13.58 3 59181 11724 29503619
Cognitive disorder 14.18 13.58 88 59096 23411 29491932
Negativism 14.11 13.58 9 59175 366 29514977
Logorrhoea 14.07 13.58 20 59164 2268 29513075
Fungal infection 13.89 13.58 5 59179 13680 29501663
Psoriatic arthropathy 13.87 13.58 6 59178 14685 29500658
Hyperosmolar state 13.81 13.58 9 59175 380 29514963
Oxygen saturation decreased 13.79 13.58 45 59139 44892 29470451
Lethargy 13.74 13.58 125 59059 37455 29477888
Adjusted calcium increased 13.74 13.58 4 59180 20 29515323
Pulmonary fibrosis 13.73 13.58 7 59177 15575 29499768
Impaired healing 13.68 13.58 5 59179 13553 29501790
Mobility decreased 13.62 13.58 19 59165 25761 29489582
Erythrosis 13.61 13.58 5 59179 57 29515286
Hangover 13.58 13.58 13 59171 964 29514379

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 1833.98 11.86 708 112242 10802 64374980
Tardive dyskinesia 1746.87 11.86 643 112307 8535 64377247
Dystonia 1561.76 11.86 729 112221 18136 64367646
Neuroleptic malignant syndrome 1544.63 11.86 791 112159 24205 64361577
Extrapyramidal disorder 1445.58 11.86 699 112251 18853 64366929
Psychotic disorder 1240.61 11.86 766 112184 33812 64351970
Sedation 1182.57 11.86 795 112155 40667 64345115
Suicide attempt 1096.87 11.86 944 112006 70063 64315719
Parkinsonism 1056.71 11.86 512 112438 13861 64371921
Dyskinesia 1056.10 11.86 727 112223 38661 64347121
Delusion 1003.66 11.86 532 112418 17482 64368300
Sexual dysfunction 845.32 11.86 345 112605 6126 64379656
Product use in unapproved indication 842.95 11.86 1274 111676 175344 64210438
Suicidal ideation 821.39 11.86 780 112170 65762 64320020
Weight increased 814.45 11.86 1390 111560 211958 64173824
Blood prolactin abnormal 811.94 11.86 267 112683 2465 64383317
Hallucination, auditory 782.43 11.86 442 112508 16497 64369285
Anosognosia 621.54 11.86 220 112730 2585 64383197
Mania 591.96 11.86 364 112586 15922 64369860
Aggression 574.22 11.86 544 112406 45688 64340094
Treatment noncompliance 557.96 11.86 521 112429 42961 64342821
Hyperprolactinaemia 555.89 11.86 224 112726 3841 64381941
Disturbance in social behaviour 541.25 11.86 217 112733 3670 64382112
Schizophrenia 539.04 11.86 300 112650 10868 64374914
Agitation 499.00 11.86 691 112259 87676 64298106
Restlessness 488.05 11.86 465 112485 39320 64346462
Tremor 481.65 11.86 901 112049 147329 64238453
Metabolic disorder 476.35 11.86 244 112706 7453 64378329
Oculogyric crisis 450.42 11.86 169 112781 2369 64383413
Abnormal behaviour 429.63 11.86 402 112548 33220 64352562
Gambling disorder 406.18 11.86 145 112805 1749 64384033
Muscle rigidity 399.85 11.86 293 112657 17180 64368602
Salivary hypersecretion 395.59 11.86 253 112697 11860 64373922
Drug interaction 391.43 11.86 1456 111494 360627 64025155
Intentional self-injury 389.94 11.86 357 112593 28687 64357095
Personality change 366.68 11.86 213 112737 8380 64377402
Anxiety 355.87 11.86 964 111986 201685 64184097
Prescribed underdose 332.90 11.86 266 112684 17749 64368033
Somnolence 325.30 11.86 936 112014 202709 64183073
Irritability 319.42 11.86 357 112593 36389 64349393
Psychotic symptom 317.33 11.86 125 112825 2013 64383769
Catatonia 307.02 11.86 182 112768 7438 64378344
Psychiatric decompensation 303.58 11.86 126 112824 2337 64383445
Arthralgia 302.47 11.86 202 112748 442058 63943724
Diarrhoea 299.22 11.86 505 112445 722199 63663583
Blood creatine phosphokinase increased 296.62 11.86 435 112515 58123 64327659
Dyspnoea 294.02 11.86 506 112444 718168 63667614
Intentional overdose 277.33 11.86 535 112415 89409 64296373
Psychomotor hyperactivity 270.48 11.86 215 112735 14236 64371546
Psychiatric symptom 268.99 11.86 156 112794 6117 64379665
Thinking abnormal 262.62 11.86 193 112757 11363 64374419
Febrile neutropenia 255.89 11.86 19 112931 187638 64198144
Anaemia 237.90 11.86 189 112761 378491 64007291
Electrocardiogram QT prolonged 230.87 11.86 461 112489 78987 64306795
Joint swelling 230.71 11.86 48 112902 215334 64170448
Pain 230.34 11.86 385 112565 553126 63832656
Stubbornness 227.39 11.86 61 112889 250 64385532
Pneumonia 220.33 11.86 403 112547 559173 63826609
Social avoidant behaviour 216.02 11.86 121 112829 4436 64381346
Galactorrhoea 213.63 11.86 107 112843 3112 64382670
Blood prolactin increased 204.37 11.86 107 112843 3421 64382361
Hypersexuality 203.93 11.86 82 112868 1397 64384385
Persecutory delusion 201.45 11.86 112 112838 4046 64381736
Prescribed overdose 200.20 11.86 211 112739 20120 64365662
Infusion related reaction 199.79 11.86 26 112924 164441 64221341
Paranoia 196.41 11.86 189 112761 16163 64369619
Serotonin syndrome 191.96 11.86 287 112663 38995 64346787
Maternal exposure during pregnancy 188.32 11.86 476 112474 95408 64290374
Mental impairment 187.12 11.86 184 112766 16159 64369623
Cough 186.91 11.86 153 112797 301995 64083787
Apathy 182.66 11.86 154 112796 11078 64374704
Off label use 180.52 11.86 1794 111156 631012 63754770
Overdose 175.40 11.86 646 112304 158920 64226862
Blood glucose increased 173.28 11.86 468 112482 97605 64288177
Hallucination 172.79 11.86 389 112561 72399 64313383
Cogwheel rigidity 169.47 11.86 88 112862 2765 64383017
Obsessive-compulsive disorder 168.22 11.86 105 112845 4713 64381069
Drooling 166.02 11.86 108 112842 5211 64380571
Obesity 157.17 11.86 187 112763 20375 64365407
Hypomania 155.24 11.86 106 112844 5548 64380234
Emotional poverty 154.76 11.86 55 112895 654 64385128
Swelling 153.46 11.86 45 112905 160173 64225609
Underdose 153.18 11.86 207 112743 25622 64360160
Orthostatic hypertension 152.60 11.86 53 112897 586 64385196
Rheumatoid arthritis 152.23 11.86 49 112901 164245 64221537
Synovitis 150.92 11.86 5 112945 99085 64286697
Priapism 150.02 11.86 91 112859 3879 64381903
Drug monitoring procedure incorrectly performed 146.98 11.86 46 112904 356 64385426
Metabolic syndrome 146.91 11.86 75 112875 2273 64383509
Malignant neoplasm progression 146.74 11.86 14 112936 112857 64272925
Schizoaffective disorder 145.85 11.86 66 112884 1521 64384261
Gestational diabetes 144.54 11.86 101 112849 5489 64380293
Bruxism 144.53 11.86 86 112864 3538 64382244
Disease progression 142.82 11.86 36 112914 141644 64244138
Mental disorder 139.01 11.86 200 112750 26245 64359537
Insomnia 138.64 11.86 699 112251 197137 64188645
Acute kidney injury 136.11 11.86 373 112577 448867 63936915
Diabetes mellitus 133.61 11.86 333 112617 66141 64319641
Sinusitis 132.59 11.86 45 112905 145883 64239899
Arthropathy 129.37 11.86 27 112923 120940 64264842
Antipsychotic drug level increased 128.96 11.86 91 112859 5024 64380758
Mood altered 128.23 11.86 149 112801 15830 64369952
Tic 128.12 11.86 71 112879 2548 64383234
Depression 126.58 11.86 645 112305 182646 64203136
Muscle twitching 124.63 11.86 160 112790 18838 64366944
Hostility 122.34 11.86 65 112885 2142 64383640
Homicidal ideation 121.38 11.86 74 112876 3183 64382599
Insurance issue 120.42 11.86 70 112880 2756 64383026
Nasopharyngitis 115.40 11.86 104 112846 195969 64189813
Rash 114.08 11.86 416 112534 458133 63927649
Compulsive shopping 113.81 11.86 45 112905 732 64385050
Infection 111.29 11.86 96 112854 184784 64200998
Compulsive sexual behaviour 110.09 11.86 33 112917 217 64385565
Fatigue 109.75 11.86 815 112135 747915 63637867
Suppressed lactation 108.76 11.86 34 112916 262 64385520
Affective disorder 108.61 11.86 91 112859 6489 64379293
Hypothermia 108.52 11.86 153 112797 19703 64366079
Urinary incontinence 107.63 11.86 212 112738 35939 64349843
Drug abuse 106.62 11.86 487 112463 131887 64253895
Increased appetite 106.53 11.86 109 112841 10037 64375745
Pruritus 105.67 11.86 245 112705 312155 64073627
Disinhibition 104.80 11.86 59 112891 2184 64383598
Pain in extremity 104.69 11.86 235 112715 302850 64082932
Back pain 103.74 11.86 174 112776 249997 64135785
Posture abnormal 103.47 11.86 68 112882 3338 64382444
Impulsive behaviour 103.10 11.86 62 112888 2601 64383181
Libido increased 102.86 11.86 54 112896 1736 64384046
Logorrhoea 101.84 11.86 72 112878 3987 64381795
Torticollis 101.00 11.86 57 112893 2120 64383662
General physical health deterioration 99.61 11.86 127 112823 204298 64181484
Dysarthria 99.42 11.86 278 112672 59128 64326654
Drug ineffective 99.05 11.86 2039 110911 838208 63547574
Drug hypersensitivity 98.98 11.86 165 112785 237650 64148132
Contraindicated product administered 98.37 11.86 33 112917 107796 64277986
Abdominal discomfort 97.71 11.86 105 112845 182217 64203565
Sepsis 97.55 11.86 158 112792 230183 64155599
Systemic lupus erythematosus 97.33 11.86 11 112939 77601 64308181
Abdominal pain 97.02 11.86 256 112694 312119 64073663
Sopor 96.97 11.86 181 112769 29480 64356302
Pyrexia 96.85 11.86 578 112372 558066 63827716
Bradykinesia 96.63 11.86 85 112865 6475 64379307
Trismus 96.18 11.86 75 112875 4826 64380956
Economic problem 95.39 11.86 55 112895 2132 64383650
Thrombocytopenia 95.26 11.86 153 112797 223648 64162134
Neuropathy peripheral 94.04 11.86 44 112906 117481 64268301
Depressive symptom 93.03 11.86 71 112879 4425 64381357
Product administered to patient of inappropriate age 91.58 11.86 71 112879 4530 64381252
Nausea 91.56 11.86 908 112042 784892 63600890
Peripheral swelling 90.89 11.86 141 112809 209012 64176770
Gastrointestinal haemorrhage 90.77 11.86 60 112890 132252 64253530
Affect lability 89.74 11.86 94 112856 8896 64376886
Rhabdomyolysis 89.71 11.86 358 112592 91368 64294414
Hyperphagia 89.12 11.86 53 112897 2178 64383604
Hypersensitivity 88.70 11.86 129 112821 196323 64189459
Caesarean section 88.58 11.86 104 112846 11170 64374612
Oppositional defiant disorder 88.56 11.86 33 112917 453 64385329
Cardiac failure congestive 88.52 11.86 60 112890 130520 64255262
Sleep disorder 87.98 11.86 267 112683 59442 64326340
Atrial fibrillation 87.88 11.86 102 112848 170987 64214795
Stomatitis 87.75 11.86 41 112909 109564 64276218
Pleural effusion 87.35 11.86 57 112893 126502 64259280
Personality disorder 83.70 11.86 68 112882 4643 64381139
Rabbit syndrome 83.63 11.86 29 112921 319 64385463
Gaze palsy 82.59 11.86 53 112897 2497 64383285
Stupor 82.56 11.86 75 112875 5960 64379822
Drug intolerance 82.38 11.86 126 112824 187866 64197916
Amenorrhoea 81.21 11.86 77 112873 6462 64379320
Gambling 80.89 11.86 27 112923 262 64385520
Euphoric mood 80.69 11.86 77 112873 6514 64379268
Disturbance in attention 80.67 11.86 204 112746 40870 64344912
Impulse-control disorder 80.29 11.86 44 112906 1544 64384238
Seizure 79.79 11.86 533 112417 166359 64219423
Erythema 78.55 11.86 129 112821 186941 64198841
Myocarditis 78.25 11.86 121 112829 16922 64368860
Depressed mood 77.75 11.86 201 112749 40811 64344971
Completed suicide 77.58 11.86 664 112286 223750 64162032
Ascites 77.21 11.86 9 112941 61992 64323790
Blood triglycerides increased 77.09 11.86 127 112823 18739 64367043
Urticaria 76.54 11.86 87 112863 147230 64238552
Asthenia 75.61 11.86 440 112510 427604 63958178
Antipsychotic drug level below therapeutic 75.11 11.86 36 112914 949 64384833
Impaired healing 74.75 11.86 9 112941 60464 64325318
Paradoxical drug reaction 73.98 11.86 71 112879 6049 64379733
Glossodynia 72.19 11.86 13 112937 64683 64321099
Infarction 72.13 11.86 58 112892 3902 64381880
Coma 71.75 11.86 324 112626 87291 64298491
Normal newborn 71.40 11.86 67 112883 5550 64380232
Mucosal inflammation 71.10 11.86 12 112938 62572 64323210
Mood swings 70.58 11.86 117 112833 17351 64368431
Acute psychosis 70.58 11.86 56 112894 3696 64382086
Renal failure 70.19 11.86 132 112818 181556 64204226
Live birth 69.80 11.86 92 112858 11112 64374670
Abortion spontaneous 69.52 11.86 143 112807 25000 64360782
Lower respiratory tract infection 68.91 11.86 40 112910 94574 64291208
Musculoskeletal pain 68.89 11.86 28 112922 81266 64304516
Enuresis 68.86 11.86 49 112901 2741 64383041
Altered state of consciousness 68.02 11.86 182 112768 37720 64348062
Speech disorder 68 11.86 213 112737 48228 64337554
Bradyphrenia 67.72 11.86 83 112867 9323 64376459
Pleurothotonus 67.61 11.86 45 112905 2257 64383525
Hospitalisation 67.59 11.86 286 112664 74921 64310861
Sudden death 67.40 11.86 124 112826 19972 64365810
Blunted affect 66.96 11.86 26 112924 402 64385380
Inappropriate affect 65.99 11.86 36 112914 1252 64384530
Water intoxication 65.17 11.86 30 112920 720 64385062
Blepharospasm 64.83 11.86 51 112899 3324 64382458
Bronchitis 64.75 11.86 57 112893 108686 64277096
Arthritis 64.58 11.86 33 112917 83781 64302001
Herpes zoster 64.35 11.86 29 112921 79158 64306624
International normalised ratio increased 64.32 11.86 29 112921 79138 64306644
Melaena 63.71 11.86 9 112941 53539 64332243
Upper respiratory tract infection 63.43 11.86 24 112926 72761 64313021
Septic shock 63.11 11.86 55 112895 105382 64280400
Hyperkalaemia 62.68 11.86 51 112899 101078 64284704
Osteoarthritis 62.07 11.86 17 112933 63319 64322463
Antipsychotic drug level decreased 61.53 11.86 31 112919 913 64384869
Haemoptysis 61.37 11.86 7 112943 49041 64336741
Victim of child abuse 60.90 11.86 30 112920 841 64384941
Alopecia 60.86 11.86 124 112826 165566 64220216
Withdrawal syndrome 60.75 11.86 130 112820 23362 64362420
Urinary retention 60.66 11.86 207 112743 48994 64336788
Bipolar I disorder 60.33 11.86 38 112912 1733 64384049
Dysphagia 60.28 11.86 356 112594 106456 64279326
Keratoconus 59.75 11.86 16 112934 65 64385717
Interstitial lung disease 59.69 11.86 50 112900 97682 64288100
Coronary artery disease 59.64 11.86 16 112934 60417 64325365
Oromandibular dystonia 59.56 11.86 30 112920 883 64384899
Blood prolactin decreased 59.22 11.86 21 112929 248 64385534
Anger 59.05 11.86 102 112848 15639 64370143
Psychomotor skills impaired 59.00 11.86 51 112899 3794 64381988
Colitis 58.92 11.86 15 112935 58659 64327123
Stereotypy 58.87 11.86 29 112921 813 64384969
Self-injurious ideation 58.61 11.86 47 112903 3150 64382632
Wrong technique in product usage process 58.31 11.86 247 112703 64727 64321055
Haemoglobin decreased 57.40 11.86 164 112786 194899 64190883
Sinus tachycardia 57.19 11.86 154 112796 32034 64353748
Hyperhidrosis 56.72 11.86 394 112556 124526 64261256
Plasma cell myeloma 56.60 11.86 7 112943 46068 64339714
Granulocytopenia 56.39 11.86 80 112870 10360 64375422
Discomfort 56.37 11.86 36 112914 80842 64304940
Flat affect 56.23 11.86 37 112913 1820 64383962
Pregnancy 55.73 11.86 117 112833 20748 64365034
Skin ulcer 55.72 11.86 6 112944 43968 64341814
Soliloquy 55.69 11.86 25 112925 565 64385217
Tachycardia 55.61 11.86 450 112500 149129 64236653
Epistaxis 55.40 11.86 54 112896 98077 64287705
Restless legs syndrome 55.38 11.86 104 112846 17012 64368770
Parkinsonian rest tremor 55.23 11.86 20 112930 252 64385530
Hypoxia 55.19 11.86 44 112906 88105 64297677
Hypokinesia 55.15 11.86 102 112848 16494 64369288
Wheezing 54.63 11.86 37 112913 80542 64305240
Abdominal pain upper 54.61 11.86 143 112807 174887 64210895
Psychomotor retardation 53.53 11.86 55 112895 5088 64380694
Dystonic tremor 53.53 11.86 18 112932 179 64385603
Decreased appetite 53.50 11.86 282 112668 281007 64104775
Product substitution issue 53.46 11.86 105 112845 17756 64368026
Symptom recurrence 53.31 11.86 28 112922 901 64384881
Cytomegalovirus infection 52.93 11.86 3 112947 37196 64348586
Pancytopenia 52.84 11.86 107 112843 143202 64242580
Decreased eye contact 52.45 11.86 26 112924 739 64385043
Pneumonitis 52.29 11.86 12 112938 50353 64335429
Delusion of grandeur 52.14 11.86 24 112926 576 64385206
Reduced facial expression 51.90 11.86 37 112913 2076 64383706
Pregnancy on contraceptive 51.63 11.86 26 112924 765 64385017
Poisoning deliberate 51.52 11.86 88 112862 13370 64372412
Cerebral haemorrhage 51.42 11.86 13 112937 51077 64334705
Rectal haemorrhage 51.23 11.86 22 112928 61795 64323987
Mobility decreased 51.10 11.86 45 112905 85795 64299987
Depressed level of consciousness 50.93 11.86 279 112671 81157 64304625
Bipolar disorder 50.85 11.86 61 112889 6700 64379082
Mutism 50.84 11.86 36 112914 1998 64383784
Multiple organ dysfunction syndrome 50.41 11.86 62 112888 101351 64284431
Eye movement disorder 50.21 11.86 62 112888 7017 64378765
Gastrointestinal disorder 49.91 11.86 50 112900 89659 64296123
Death 49.85 11.86 573 112377 482132 63903650
Dyspnoea exertional 49.79 11.86 34 112916 73696 64312086
Headache 49.58 11.86 642 112308 528825 63856957
Accommodation disorder 49.14 11.86 22 112928 494 64385288
Osteonecrosis of jaw 49.04 11.86 6 112944 39819 64345963
Trimethylaminuria 48.90 11.86 16 112934 145 64385637
Bone marrow failure 48.65 11.86 12 112938 47940 64337842
Abortion induced 48.65 11.86 58 112892 6330 64379452
Type 2 diabetes mellitus 48.12 11.86 150 112800 33870 64351912
Cardiac failure 47.81 11.86 100 112850 132273 64253509
Hyperthermia 47.25 11.86 92 112858 15458 64370324
Therapeutic product effect decreased 47.05 11.86 81 112869 115270 64270512
Haematochezia 47.01 11.86 29 112921 66344 64319438
Cognitive disorder 46.05 11.86 205 112745 54882 64330900
Abortion 45.85 11.86 28 112922 1208 64384574
Hypertonia 45.84 11.86 56 112894 6269 64379513
Obsessive thoughts 45.49 11.86 26 112924 991 64384791
Haematuria 44.84 11.86 25 112925 60446 64325336
Hallucinations, mixed 44.54 11.86 54 112896 5998 64379784
Vertigo 44.45 11.86 213 112737 58798 64326984
Accidental exposure to product by child 44.42 11.86 36 112914 2449 64383333
Antipsychotic drug level above therapeutic 44.36 11.86 32 112918 1829 64383953
Bankruptcy 44.16 11.86 11 112939 31 64385751
Electrocardiogram QT shortened 44.15 11.86 16 112934 202 64385580
Neoplasm progression 44.07 11.86 9 112941 40955 64344827
Pneumonia aspiration 43.97 11.86 213 112737 59058 64326724
Homosexuality 43.90 11.86 11 112939 32 64385750
Injection site erythema 43.50 11.86 36 112914 70764 64315018
Mydriasis 43.41 11.86 88 112862 15224 64370558
Lactic acidosis 43.26 11.86 27 112923 61383 64324399
Physical assault 42.48 11.86 29 112921 1517 64384265
Urinary tract infection 42.46 11.86 235 112715 231361 64154421
Acute myocardial infarction 42.16 11.86 36 112914 69682 64316100
Wound 42.11 11.86 43 112907 76434 64309348
Dehydration 41.93 11.86 216 112734 216547 64169235
Delusional disorder, unspecified type 41.80 11.86 22 112928 711 64385071
Sedation complication 41.36 11.86 69 112881 10285 64375497
Threatened labour 41.12 11.86 20 112930 545 64385237
Cellulitis 40.78 11.86 63 112887 93594 64292188
Hiccups 40.62 11.86 61 112889 8315 64377467
Influenza 40.59 11.86 78 112872 106453 64279329
Delirium 40.57 11.86 233 112717 68961 64316821
Hypercalcaemia 40.54 11.86 4 112946 31412 64354370
Type 1 diabetes mellitus 40.52 11.86 50 112900 5655 64380127
Diverticulitis 40.49 11.86 9 112941 38609 64347173
Sleep-related eating disorder 40.40 11.86 21 112929 661 64385121
Blood pressure systolic increased 40.35 11.86 18 112932 49435 64336347
Floppy iris syndrome 40.34 11.86 17 112933 328 64385454
Vomiting 40.29 11.86 701 112249 550416 63835366
Dyslipidaemia 40.18 11.86 64 112886 9178 64376604
Psychotic behaviour 39.94 11.86 24 112926 1005 64384777
Movement disorder 39.83 11.86 106 112844 21894 64363888
Choreoathetosis 39.42 11.86 27 112923 1420 64384362
Feeling guilty 39.41 11.86 22 112928 801 64384981
Blood creatinine increased 39.31 11.86 115 112835 135667 64250115
Chills 39.20 11.86 117 112833 137147 64248635
Autonomic nervous system imbalance 39.10 11.86 42 112908 4090 64381692
Palmar-plantar erythrodysaesthesia syndrome 39.01 11.86 3 112947 28816 64356966
Intentional product use issue 38.85 11.86 67 112883 95297 64290485
Parkinsonian gait 38.77 11.86 22 112928 827 64384955
Dysphoria 38.74 11.86 43 112907 4345 64381437
Eosinophilic myocarditis 38.69 11.86 22 112928 830 64384952
Lactation disorder 38.62 11.86 14 112936 177 64385605
Ataxia 38.57 11.86 105 112845 21979 64363803
Platelet count decreased 38.45 11.86 157 112793 167554 64218228
Sexually inappropriate behaviour 38.43 11.86 18 112932 450 64385332
Fluid retention 38.27 11.86 29 112921 59577 64326205
Productive cough 38.26 11.86 43 112907 73160 64312622
Paraesthesia 38.17 11.86 115 112835 134407 64251375
Somnambulism 38.04 11.86 46 112904 5095 64380687
Suicidal behaviour 37.78 11.86 35 112915 2852 64382930
Abulia 37.78 11.86 22 112928 869 64384913
Blister 37.66 11.86 52 112898 80915 64304867
Tachyphrenia 37.45 11.86 29 112921 1847 64383935
Exhibitionism 37.27 11.86 10 112940 41 64385741
Schizophreniform disorder 37.25 11.86 13 112937 146 64385636
Renal impairment 37.19 11.86 117 112833 134900 64250882
Staring 37.05 11.86 32 112918 2378 64383404
Delusional disorder, persecutory type 36.89 11.86 17 112933 409 64385373
Negative thoughts 36.87 11.86 25 112925 1293 64384489
Chest discomfort 36.86 11.86 94 112856 116012 64269770
Acute myeloid leukaemia 36.78 11.86 3 112947 27460 64358322
Irritable bowel syndrome 36.67 11.86 10 112940 37359 64348423
Weight decreased 36.58 11.86 322 112628 285417 64100365
Myocardial infarction 36.30 11.86 158 112792 165663 64220119
Folliculitis 35.91 11.86 5 112945 30072 64355710
Akinesia 35.86 11.86 35 112915 3044 64382738
Antidepressant drug level above therapeutic 35.61 11.86 18 112932 534 64385248
Crying 35.57 11.86 96 112854 19994 64365788
Oedema peripheral 35.56 11.86 219 112731 210098 64175684
Hyperkinesia 35.53 11.86 32 112918 2514 64383268
Injection site pruritus 35.51 11.86 11 112939 37815 64347967
Resting tremor 35.28 11.86 25 112925 1389 64384393
Abdominal distension 35.10 11.86 72 112878 95922 64289860
Divorced 35.00 11.86 9 112941 30 64385752
Paraphilia 34.87 11.86 10 112940 55 64385727
Contusion 34.85 11.86 94 112856 113871 64271911
Basal cell carcinoma 34.83 11.86 6 112944 30832 64354950
Bone pain 34.79 11.86 20 112930 47552 64338230
Chest pain 34.29 11.86 257 112693 235723 64150059
Anaphylactic reaction 34.09 11.86 42 112908 68622 64317160
Morbid thoughts 33.66 11.86 19 112931 707 64385075
Polydipsia 33.52 11.86 46 112904 5775 64380007
Hepatotoxicity 33.47 11.86 14 112936 39948 64345834
Hepatic enzyme increased 33.45 11.86 116 112834 129827 64255955
Ideas of reference 33.29 11.86 12 112938 149 64385633
Hyperreflexia 33.16 11.86 51 112899 7097 64378685
Alice in wonderland syndrome 33.15 11.86 9 112941 39 64385743
Diabetic coma 32.95 11.86 22 112928 1109 64384673
Neutrophil count increased 32.87 11.86 108 112842 25066 64360716
Hallucination, olfactory 32.79 11.86 16 112934 439 64385343
Negative symptoms in schizophrenia 32.75 11.86 11 112939 109 64385673
Refusal of treatment by patient 32.55 11.86 55 112895 8284 64377498
Muscle injury 32.51 11.86 4 112946 26433 64359349
Psychosexual disorder 32.48 11.86 11 112939 112 64385670
Blood pressure fluctuation 32.33 11.86 26 112924 51845 64333937
Drug effective for unapproved indication 32.16 11.86 36 112914 3672 64382110
Disturbance in sexual arousal 32.05 11.86 12 112938 167 64385615
Malaise 31.54 11.86 496 112454 395751 63990031
Ill-defined disorder 31.54 11.86 19 112931 44033 64341749
Dry skin 31.44 11.86 26 112924 51135 64334647
Epilepsy 31.27 11.86 129 112821 33402 64352380
Loss of libido 31.18 11.86 29 112921 2375 64383407
Poor quality sleep 31.02 11.86 88 112862 18863 64366919
Head titubation 30.98 11.86 19 112931 826 64384956
Muscle contractions involuntary 30.97 11.86 33 112917 3184 64382598
Social problem 30.85 11.86 22 112928 1235 64384547
Slow response to stimuli 30.82 11.86 24 112926 1541 64384241
Drug level increased 30.67 11.86 130 112820 34066 64351716
Food craving 30.60 11.86 23 112927 1401 64384381
Analgesic drug level above therapeutic 30.50 11.86 15 112935 419 64385363
Inappropriate antidiuretic hormone secretion 30.35 11.86 97 112853 22192 64363590
Osteoporosis 30.33 11.86 18 112932 42062 64343720
Heat stroke 30.15 11.86 23 112927 1432 64384350
Patient restraint 30.15 11.86 10 112940 95 64385687
COVID-19 30.13 11.86 42 112908 65098 64320684
Muscle contracture 30.01 11.86 27 112923 2118 64383664
Binge eating 29.98 11.86 15 112935 435 64385347
Neutropenic sepsis 29.93 11.86 3 112947 23269 64362513
Behaviour disorder 29.92 11.86 38 112912 4424 64381358
Gastric ulcer 29.84 11.86 8 112942 30226 64355556
Myelodysplastic syndrome 29.79 11.86 6 112944 27573 64358209
Birdshot chorioretinopathy 29.66 11.86 9 112941 62 64385720
Hypervolaemia 29.60 11.86 15 112935 38270 64347512
Grandiosity 29.52 11.86 16 112934 549 64385233
Vision blurred 29.47 11.86 264 112686 90052 64295730
Hip fracture 29.06 11.86 6 112944 27093 64358689
Coordination abnormal 29.04 11.86 74 112876 14890 64370892
Hypotension 28.95 11.86 481 112469 380493 64005289
Nuchal rigidity 28.85 11.86 19 112931 936 64384846
Conversion disorder 28.84 11.86 24 112926 1695 64384087
Homeless 28.84 11.86 10 112940 110 64385672
Pulmonary mass 28.65 11.86 4 112946 24012 64361770
Subdural haematoma 28.50 11.86 7 112943 28047 64357735
Electrocardiogram QRS complex prolonged 28.46 11.86 55 112895 9189 64376593
Chronic kidney disease 28.16 11.86 36 112914 57883 64327899
High-grade B-cell lymphoma 28.07 11.86 9 112941 76 64385706
Target skin lesion 28.05 11.86 10 112940 120 64385662
Cataract 28.02 11.86 29 112921 51233 64334549
Tongue movement disturbance 28.01 11.86 13 112937 318 64385464
Oedema 27.98 11.86 76 112874 91859 64293923
Diabetic ketoacidosis 27.97 11.86 115 112835 29730 64356052
Psoriatic arthropathy 27.85 11.86 21 112929 43260 64342522
Drug screen false positive 27.85 11.86 19 112931 993 64384789
Tension 27.83 11.86 34 112916 3806 64381976
Red blood cell sedimentation rate increased 27.72 11.86 10 112940 31225 64354557
Negativism 27.64 11.86 17 112933 743 64385039
Verbal abuse 27.54 11.86 12 112938 252 64385530
Thrombosis 27.54 11.86 51 112899 70591 64315191
Pulmonary fibrosis 27.49 11.86 9 112941 29869 64355913
Respiratory failure 27.15 11.86 168 112782 161015 64224767
Substance abuse 27.05 11.86 54 112896 9238 64376544
Lung neoplasm malignant 26.98 11.86 3 112947 21445 64364337
Device related infection 26.85 11.86 10 112940 30616 64355166
Electroencephalogram abnormal 26.82 11.86 39 112911 5164 64380618
Antisocial behaviour 26.82 11.86 15 112935 548 64385234
Premature labour 26.80 11.86 48 112902 7572 64378210
Oxygen saturation decreased 26.70 11.86 97 112853 107079 64278703
Autism spectrum disorder 26.69 11.86 18 112932 923 64384859
Gynaecomastia 26.62 11.86 42 112908 5974 64379808
Generalised tonic-clonic seizure 26.57 11.86 139 112811 39718 64346064
Full blood count decreased 26.39 11.86 4 112946 22578 64363204
Pericarditis 26.31 11.86 43 112907 62473 64323309
Haemorrhage intracranial 26.21 11.86 5 112945 23879 64361903
Suspiciousness 26.14 11.86 15 112935 576 64385206
Myoclonus 26.13 11.86 100 112850 25018 64360764
Diabetic hyperosmolar coma 26.00 11.86 16 112934 700 64385082
Cytokine release syndrome 25.99 11.86 3 112947 20826 64364956
Uterine dilation and curettage 25.92 11.86 14 112936 477 64385305
Hallucination, visual 25.89 11.86 107 112843 27727 64358055
Respiratory depression 25.77 11.86 95 112855 23348 64362434
Hypoprolactinaemia 25.53 11.86 6 112944 12 64385770
Epidural lipomatosis 25.41 11.86 17 112933 860 64384922
Osteonecrosis 25.11 11.86 9 112941 28220 64357562
Personal relationship issue 24.94 11.86 10 112940 169 64385613
Distractibility 24.90 11.86 15 112935 631 64385151
Libido decreased 24.87 11.86 36 112914 4748 64381034
Pneumothorax 24.80 11.86 6 112944 24292 64361490
Compulsions 24.44 11.86 12 112938 334 64385448
Soft tissue injury 24.34 11.86 21 112929 1558 64384224
Somatic hallucination 24.33 11.86 7 112943 39 64385743
Nasal congestion 24.22 11.86 42 112908 59616 64326166
Intention tremor 23.87 11.86 15 112935 681 64385101
Inappropriate schedule of product administration 23.87 11.86 257 112693 92029 64293753
Injection site pain 23.86 11.86 107 112843 111301 64274481
Basilar artery occlusion 23.82 11.86 10 112940 191 64385591
No adverse event 23.65 11.86 106 112844 28455 64357327
Drug withdrawal syndrome 23.60 11.86 113 112837 31178 64354604
Screaming 23.58 11.86 30 112920 3499 64382283
Hypocalcaemia 23.53 11.86 23 112927 41730 64344052
Renal tubular necrosis 23.49 11.86 5 112945 22105 64363677
Major depression 23.45 11.86 46 112904 7770 64378012
Bladder dilatation 23.34 11.86 22 112928 1832 64383950
Inflammation 23.01 11.86 50 112900 65250 64320532
Persistent depressive disorder 23.00 11.86 17 112933 1009 64384773
Electroconvulsive therapy 22.91 11.86 8 112942 90 64385692
Drug therapy enhancement 22.89 11.86 6 112944 22 64385760
Anxiolytic therapy 22.89 11.86 6 112944 22 64385760
Post-traumatic neck syndrome 22.87 11.86 22 112928 1880 64383902
Benign ethnic neutropenia 22.85 11.86 7 112943 50 64385732
Rash erythematous 22.85 11.86 31 112919 48602 64337180
Fungal infection 22.85 11.86 16 112934 34235 64351547
Tendonitis 22.79 11.86 4 112946 20278 64365504
Rhinorrhoea 22.76 11.86 44 112906 59925 64325857
Refusal of examination 22.67 11.86 8 112942 93 64385689
Gout 22.43 11.86 5 112945 21408 64364374
Cholestasis of pregnancy 22.27 11.86 16 112934 909 64384873
Miosis 22.10 11.86 62 112888 13204 64372578
Hereditary ataxia 22.10 11.86 6 112944 26 64385756
Adrenal insufficiency 22.10 11.86 6 112944 22481 64363301
Rash maculo-papular 22.07 11.86 30 112920 46996 64338786
Prostate cancer 22.03 11.86 4 112946 19791 64365991
Grimacing 21.98 11.86 14 112936 651 64385131
Polyuria 21.96 11.86 60 112890 12583 64373199
Memory impairment 21.88 11.86 238 112712 85444 64300338
Blood pressure diastolic decreased 21.82 11.86 6 112944 22295 64363487
Haemorrhage 21.68 11.86 69 112881 79282 64306500
Sudden cardiac death 21.66 11.86 33 112917 4554 64381228
Bacteraemia 21.63 11.86 10 112940 26901 64358881
Sluggishness 21.60 11.86 37 112913 5633 64380149
Drug monitoring procedure not performed 21.60 11.86 15 112935 807 64384975
Slow speech 21.59 11.86 22 112928 2015 64383767
Pseudomyopia 21.54 11.86 7 112943 62 64385720
Delusional perception 21.49 11.86 11 112939 335 64385447
Excessive sexual fantasies 21.40 11.86 4 112946 0 64385782
Morning sickness 21.39 11.86 12 112938 441 64385341
Breast feeding 21.38 11.86 14 112936 683 64385099
Chemical burn 21.29 11.86 12 112938 445 64385337
Apraxia 21.25 11.86 24 112926 2471 64383311
Decreased activity 21.23 11.86 42 112908 7138 64378644
Compulsive hoarding 21.15 11.86 7 112943 66 64385716
Nephrogenic diabetes insipidus 21.14 11.86 21 112929 1866 64383916
Joint hyperextension 21.13 11.86 10 112940 256 64385526
Dyspepsia 21.13 11.86 71 112879 80241 64305541
Disease recurrence 21.08 11.86 110 112840 31400 64354382
Activation syndrome 20.95 11.86 10 112940 261 64385521
Haemophagocytic lymphohistiocytosis 20.85 11.86 3 112947 17606 64368176
Condition aggravated 20.77 11.86 823 112127 371603 64014179
Haemorrhoids 20.76 11.86 8 112942 23993 64361789
Dissociation 20.76 11.86 26 112924 2985 64382797
Excessive masturbation 20.69 11.86 7 112943 71 64385711
Troponin T increased 20.67 11.86 23 112927 2330 64383452
Asthma 20.67 11.86 91 112859 95134 64290648
Renal hypertension 20.57 11.86 9 112941 191 64385591
Blood pressure increased 20.52 11.86 198 112752 172354 64213428
Hunger 20.50 11.86 31 112919 4250 64381532
Tongue biting 20.49 11.86 20 112930 1740 64384042
Poriomania 20.44 11.86 9 112941 194 64385588
Knee arthroplasty 20.25 11.86 11 112939 26988 64358794
Rash pruritic 20.19 11.86 44 112906 57360 64328422
Bundle branch block right 20.15 11.86 51 112899 10218 64375564
Hypersomnia 20.10 11.86 78 112872 19639 64366143
Protrusion tongue 20.07 11.86 11 112939 386 64385396
Eosinophil count decreased 20.06 11.86 24 112926 2628 64383154
Faeces discoloured 20.01 11.86 10 112940 25719 64360063
Anterograde amnesia 19.98 11.86 13 112937 627 64385155
Blood urea increased 19.89 11.86 29 112921 44124 64341658
Cerebrovascular accident 19.89 11.86 150 112800 137433 64248349
Injection site reaction 19.73 11.86 32 112918 46632 64339150
Abortion threatened 19.67 11.86 11 112939 402 64385380
Osteomyelitis 19.60 11.86 12 112938 27575 64358207
Pulmonary arterial hypertension 19.52 11.86 10 112940 25357 64360425
Neuropsychiatric symptoms 19.43 11.86 15 112935 951 64384831
Facial nerve disorder 19.42 11.86 13 112937 658 64385124
Personality change due to a general medical condition 19.39 11.86 8 112942 146 64385636
Thrombotic microangiopathy 19.35 11.86 3 112947 16652 64369130
Sexual abuse 19.34 11.86 8 112942 147 64385635
Helplessness 19.20 11.86 10 112940 316 64385466
Atelectasis 19.18 11.86 12 112938 27254 64358528
Shoplifting 19.16 11.86 4 112946 3 64385779
Reversible cerebral vasoconstriction syndrome 19.06 11.86 22 112928 2320 64383462
Femur fracture 19.01 11.86 19 112931 34116 64351666
Angina pectoris 18.98 11.86 31 112919 45050 64340732
Localised infection 18.94 11.86 15 112935 30146 64355636
Fear of weight gain 18.94 11.86 5 112945 19 64385763
Twin pregnancy 18.91 11.86 14 112936 833 64384949
Adjusted calcium increased 18.68 11.86 6 112944 51 64385731
Lung disorder 18.60 11.86 50 112900 60650 64325132
Hemiparesis 18.52 11.86 15 112935 29812 64355970
Immunodeficiency 18.51 11.86 3 112947 16121 64369661
Musculoskeletal stiffness 18.51 11.86 311 112639 122895 64262887
Dysphemia 18.49 11.86 25 112925 3094 64382688
Initial insomnia 18.44 11.86 35 112915 5769 64380013
Meningitis streptococcal 18.36 11.86 8 112942 168 64385614
Neuroleptic-induced deficit syndrome 18.35 11.86 5 112945 22 64385760
Body dysmorphic disorder 18.35 11.86 9 112941 250 64385532
Injection site bruising 18.32 11.86 22 112928 36351 64349431
Cystitis 18.29 11.86 29 112921 42646 64343136
Hypotonia 18.29 11.86 52 112898 11160 64374622
Petechiae 18.24 11.86 5 112945 18621 64367161
Oral herpes 18.17 11.86 8 112942 22144 64363638
Taciturnity 18.16 11.86 4 112946 5 64385777
Sternal fracture 18.10 11.86 21 112929 2226 64383556
Product use issue 17.94 11.86 369 112581 151346 64234436
Chronic obstructive pulmonary disease 17.89 11.86 64 112886 70984 64314798
Clostridium difficile colitis 17.79 11.86 13 112937 27210 64358572
Locked-in syndrome 17.64 11.86 12 112938 624 64385158
Joint range of motion decreased 17.49 11.86 6 112944 19337 64366445
Skin lesion 17.40 11.86 23 112927 36459 64349323
Hypomagnesaemia 17.38 11.86 24 112926 37352 64348430
Bone disorder 17.38 11.86 4 112946 16755 64369027
Musculoskeletal chest pain 17.23 11.86 8 112942 21471 64364311
Confusional arousal 17.22 11.86 6 112944 67 64385715
Poor personal hygiene 17.22 11.86 11 112939 514 64385268
Blood thyroid stimulating hormone decreased 17.19 11.86 32 112918 5198 64380584
Metabolic acidosis 17.16 11.86 65 112885 70893 64314889
Sneezing 17.15 11.86 3 112947 15248 64370534
Myocarditis septic 17.07 11.86 5 112945 30 64385752
Spinal fracture 17.03 11.86 3 112947 15171 64370611
Gait disturbance 16.98 11.86 408 112542 171747 64214035
Nervousness 16.97 11.86 99 112851 29457 64356325
Loss of consciousness 16.94 11.86 359 112591 148006 64237776
Oropharyngeal pain 16.91 11.86 89 112861 88778 64297004
Hypoalbuminaemia 16.84 11.86 5 112945 17669 64368113
Pyramidal tract syndrome 16.79 11.86 11 112939 537 64385245
Selective mutism 16.76 11.86 6 112944 73 64385709
Blood ketone body 16.76 11.86 7 112943 132 64385650
Nightmare 16.70 11.86 77 112873 20916 64364866
Injection site haemorrhage 16.65 11.86 11 112939 24267 64361515
Muscle tightness 16.64 11.86 50 112900 11065 64374717
Nephrolithiasis 16.62 11.86 32 112918 43651 64342131
Nephropathy toxic 16.60 11.86 5 112945 17509 64368273
Obstructive airways disorder 16.59 11.86 10 112940 23175 64362607
Treatment failure 16.58 11.86 128 112822 116688 64269094
Delusional disorder, erotomanic type 16.41 11.86 5 112945 35 64385747
Intermenstrual bleeding 16.40 11.86 31 112919 5094 64380688
Emotional disorder 16.38 11.86 54 112896 12553 64373229
Ejaculation delayed 16.29 11.86 7 112943 142 64385640
Tourette's disorder 16.26 11.86 6 112944 80 64385702
Asphyxia 16.22 11.86 45 112905 9521 64376261
Postural tremor 16.20 11.86 11 112939 570 64385212
Premature delivery 16.15 11.86 70 112880 18519 64367263
Therapeutic product effect variable 16.07 11.86 17 112933 1627 64384155
Theft 16.05 11.86 8 112942 230 64385552
Fear 16.05 11.86 74 112876 20097 64365685
Complicated fracture 16.05 11.86 3 112947 0 64385782
Pulmonary oedema 15.99 11.86 77 112873 78597 64307185
Impaired self-care 15.99 11.86 20 112930 2293 64383489
Injection site swelling 15.99 11.86 30 112920 41323 64344459
Excessive eye blinking 15.96 11.86 15 112935 1245 64384537
Disruptive mood dysregulation disorder 15.87 11.86 4 112946 12 64385770
Pregnancy with implant contraceptive 15.86 11.86 16 112934 1448 64384334
Candida infection 15.82 11.86 19 112931 31400 64354382
Hot flush 15.80 11.86 36 112914 46199 64339583
Narcolepsy 15.79 11.86 14 112936 1077 64384705
Neck pain 15.78 11.86 55 112895 61478 64324304
Red cell distribution width decreased 15.77 11.86 14 112936 1079 64384703
Drug dependence 15.65 11.86 106 112844 33206 64352576
Post procedural complication 15.58 11.86 9 112941 21344 64364438
Hip arthroplasty 15.58 11.86 9 112941 21342 64364440
Libido disorder 15.56 11.86 8 112942 246 64385536
Transfusion 15.56 11.86 6 112944 17988 64367794
Neurotoxicity 15.55 11.86 15 112935 27389 64358393
Erection increased 15.51 11.86 9 112941 353 64385429
Nodule 15.50 11.86 6 112944 17941 64367841
Erectile dysfunction 15.45 11.86 53 112897 12574 64373208
Bronchiectasis 15.43 11.86 3 112947 14137 64371645
Oropharyngeal spasm 15.33 11.86 8 112942 254 64385528
Anuria 15.31 11.86 7 112943 18957 64366825
Influenza like illness 15.26 11.86 56 112894 61646 64324136
Neuralgia 15.25 11.86 14 112936 26170 64359612
Toxic epidermal necrolysis 15.23 11.86 26 112924 37140 64348642
Communication disorder 15.21 11.86 25 112925 3681 64382101
Unevaluable event 15.16 11.86 42 112908 50447 64335335
Myopathy 15.12 11.86 6 112944 17674 64368108
Ejaculation disorder 15.09 11.86 10 112940 498 64385284
Polyneuropathy 15.07 11.86 8 112942 19886 64365896
Head banging 15.01 11.86 10 112940 502 64385280
Congestive cardiomyopathy 14.99 11.86 46 112904 10298 64375484
Night sweats 14.98 11.86 25 112925 36021 64349761
Hypoglycaemia 14.97 11.86 94 112856 89798 64295984
Gastroenteritis viral 14.85 11.86 8 112942 19721 64366061
Rebound effect 14.83 11.86 29 112921 4888 64380894
Multiple drug therapy 14.81 11.86 19 112931 2235 64383547
Gender dysphoria 14.76 11.86 5 112945 51 64385731
Exposure during pregnancy 14.72 11.86 204 112746 77471 64308311
Therapeutic product effective for unapproved indication 14.72 11.86 6 112944 106 64385676
Body mass index decreased 14.72 11.86 10 112940 519 64385263
Energy increased 14.70 11.86 21 112929 2737 64383045
Bronchospasm 14.63 11.86 10 112940 21672 64364110
Imprisonment 14.56 11.86 10 112940 528 64385254
Oesophagitis 14.56 11.86 10 112940 21620 64364162
Hepatic failure 14.55 11.86 49 112901 55345 64330437
Myalgia 14.53 11.86 193 112757 158424 64227358
Violence-related symptom 14.43 11.86 11 112939 684 64385098
Abdominal pain lower 14.43 11.86 15 112935 26454 64359328
Affective ambivalence 14.43 11.86 4 112946 19 64385763
Burning sensation 14.41 11.86 42 112908 49622 64336160
Frequent bowel movements 14.41 11.86 7 112943 18298 64367484
Muscular weakness 14.35 11.86 148 112802 127190 64258592
Feeling of despair 14.34 11.86 20 112930 2548 64383234
Megacolon 14.31 11.86 22 112928 3060 64382722
Emotional distress 14.24 11.86 110 112840 35928 64349854
Tubulointerstitial nephritis 14.22 11.86 20 112930 30889 64354893
Flight of ideas 14.21 11.86 11 112939 700 64385082
Tooth infection 14.15 11.86 4 112946 14597 64371185
Respiratory disorder 14.14 11.86 26 112924 36085 64349697
Suicide threat 14.10 11.86 5 112945 59 64385723
Dyskinesia oesophageal 14.10 11.86 5 112945 59 64385723
High density lipoprotein decreased 14.06 11.86 25 112925 3921 64381861
Hypokalaemia 14.02 11.86 141 112809 121762 64264020
Loss of employment 14.01 11.86 17 112933 1890 64383892
Multiple fractures 14.00 11.86 32 112918 6008 64379774
Dysbiosis 13.99 11.86 12 112938 883 64384899
Ear pain 13.98 11.86 14 112936 25122 64360660
Pharyngeal dyskinesia 13.95 11.86 4 112946 22 64385760
Full blood count abnormal 13.95 11.86 19 112931 29738 64356044
Gastritis 13.91 11.86 34 112916 42584 64343198
Adverse drug reaction 13.86 11.86 131 112819 45333 64340449
Spleen congestion 13.86 11.86 9 112941 433 64385349
Pseudomonas infection 13.83 11.86 7 112943 17876 64367906
Skin necrosis 13.75 11.86 4 112946 14325 64371457
Hypoacusis 13.72 11.86 15 112935 25852 64359930
Haemoglobin increased 13.70 11.86 29 112921 5172 64380610
Merycism 13.68 11.86 7 112943 213 64385569
Pseudodementia 13.66 11.86 4 112946 24 64385758
Angina unstable 13.64 11.86 5 112945 15462 64370320
Renal injury 13.59 11.86 5 112945 15424 64370358
Asocial behaviour 13.53 11.86 5 112945 67 64385715
Foot deformity 13.47 11.86 6 112944 16498 64369284
Haematemesis 13.45 11.86 40 112910 46959 64338823
Emphysema 13.37 11.86 4 112946 14065 64371717
Premature baby 13.33 11.86 22 112928 3250 64382532
Patient dissatisfaction with treatment 13.31 11.86 6 112944 137 64385645
Breast cancer 13.27 11.86 19 112931 29129 64356653
Sexually transmitted disease 13.23 11.86 6 112944 139 64385643
Limb injury 13.18 11.86 13 112937 23492 64362290
Saccadic eye movement 13.15 11.86 6 112944 141 64385641
Confusional state 13.14 11.86 571 112379 260573 64125209
Hepatic cirrhosis 13.14 11.86 16 112934 26282 64359500
Concussion 13.13 11.86 37 112913 7901 64377881
Self esteem inflated 13.11 11.86 3 112947 5 64385777
Bursitis 13.10 11.86 11 112939 21474 64364308
Right ventricular systolic pressure decreased 13.08 11.86 5 112945 74 64385708
Squamous cell carcinoma 13.08 11.86 4 112946 13865 64371917
Delusion of reference 13.03 11.86 6 112944 144 64385638
Hyperosmolar state 12.97 11.86 10 112940 633 64385149
Post-traumatic stress disorder 12.92 11.86 25 112925 4180 64381602
Epstein-Barr virus infection 12.91 11.86 3 112947 12485 64373297
Urine amphetamine positive 12.90 11.86 5 112945 77 64385705
Urate nephropathy 12.81 11.86 6 112944 150 64385632
Spontaneous ejaculation 12.76 11.86 3 112947 6 64385776
Intrapartum haemorrhage 12.76 11.86 3 112947 6 64385776
Cataplexy 12.71 11.86 11 112939 820 64384962
Troponin increased 12.63 11.86 57 112893 15342 64370440
Scrotal haematoma 12.61 11.86 5 112945 82 64385700
Dermatitis 12.59 11.86 8 112942 18021 64367761
Syringe issue 12.59 11.86 25 112925 4261 64381521
Induced labour 12.54 11.86 11 112939 835 64384947
Gastric haemorrhage 12.51 11.86 4 112946 13477 64372305
Hyperammonaemia 12.49 11.86 42 112908 9862 64375920
Musculoskeletal disorder 12.43 11.86 8 112942 17898 64367884
Medication error 12.39 11.86 138 112812 49828 64335954
Gestational hypertension 12.37 11.86 15 112935 1666 64384116
Sputum discoloured 12.37 11.86 8 112942 17848 64367934
Shock haemorrhagic 12.36 11.86 7 112943 16784 64368998
Cardiac disorder 12.31 11.86 53 112897 55763 64330019
Thermal burn 12.29 11.86 30 112920 5876 64379906
Adrenal cyst 12.28 11.86 5 112945 88 64385694
Dermatitis bullous 12.26 11.86 3 112947 12051 64373731
Scar excision 12.25 11.86 4 112946 36 64385746
Female sexual dysfunction 12.25 11.86 4 112946 36 64385746
Embolism venous 12.21 11.86 22 112928 3485 64382297
Anhedonia 12.21 11.86 52 112898 13654 64372128
Pulmonary hypertension 12.14 11.86 37 112913 43102 64342680
Mouth ulceration 12.14 11.86 24 112926 32420 64353362
Skin cancer 12.14 11.86 3 112947 11971 64373811
Psychotic disorder due to a general medical condition 12.08 11.86 7 112943 274 64385508
Device malfunction 12.08 11.86 8 112942 17625 64368157
Blood pressure diastolic abnormal 12.05 11.86 3 112947 11914 64373868
Abnormal weight gain 12.01 11.86 17 112933 2196 64383586
Therapeutic product effect incomplete 12.00 11.86 251 112699 103231 64282551
Swelling face 11.97 11.86 58 112892 59108 64326674
Trichotillomania 11.96 11.86 6 112944 175 64385607
Hypersomnia-bulimia syndrome 11.91 11.86 3 112947 9 64385773
Electrocardiogram abnormal 11.89 11.86 51 112899 13430 64372352
Breath odour 11.87 11.86 14 112936 1510 64384272

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enterococcal sepsis 27.81 20.46 10 983 10 83675
Right ventricular false tendon 27.81 20.46 10 983 10 83675
Dehydration 21.86 20.46 26 967 405 83280
Hypernatraemia 21.58 20.46 25 968 378 83307

Pharmacologic Action:

SourceCodeDescription
ATC N05AX12 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Other antipsychotics
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D000928 Antidepressive Agents
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018492 Dopamine Antagonists
MeSH PA D065127 Dopamine D2 Receptor Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D058830 Serotonin 5-HT2 Receptor Antagonists
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35941 serotonin agonists
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:65191 atypical antipsychotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Infantile autism indication 408857007
Agitation associated with Bipolar Mania indication
Depression Treatment Adjunct indication
Agitation associated with Schizophrenia indication
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Alzheimer's disease contraindication 26929004 DOID:10652
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Hyperlipidemia contraindication 55822004 DOID:1168
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Leukopenia contraindication 84828003 DOID:615
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Metabolic syndrome X contraindication 237602007 DOID:14221
Esophageal dysmotility contraindication 266434009 DOID:9192
Neutropenic disorder contraindication 303011007 DOID:1227
At risk for aspiration contraindication 371736008
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.84 Basic
pKa2 0.67 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
9.75MG/1.3ML (7.5MG/ML) ABILIFY OTSUKA N021866 Sept. 20, 2006 DISCN INJECTABLE INTRAMUSCULAR 7115587 July 21, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10980803 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 11154553 Sept. 24, 2033 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.90 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR PARTIAL AGONIST Ki 8.71 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1A GPCR PARTIAL AGONIST Ki 8.15 WOMBAT-PK DRUG LABEL
Alpha-2A adrenergic receptor GPCR Ki 7.13 PDSP
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 6.22 CHEMBL
Multidrug resistance protein 1 Transporter IC50 6.11 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.83 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.68 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 9.44 PDSP
5-hydroxytryptamine receptor 2C GPCR Ki 7.36 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 6.51 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.69 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 7.24 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.99 PDSP
D(3) dopamine receptor GPCR Ki 8.53 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 5.68 PDSP
Histamine H1 receptor GPCR Ki 7.22 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 5.17 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.46 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5.33 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.82 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.63 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.10 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 7.20 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.42 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.49 PDSP
D(4) dopamine receptor GPCR Ki 6.65 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.20 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.46 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 5.91 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.10 PDSP
Beta-1 adrenergic receptor GPCR Ki 6.85 PDSP
Histone H1.0 Nuclear other Ki 7.55 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.79 PDSP
D(1A) dopamine receptor GPCR Ki 6.06 PDSP
Histamine H1 receptor GPCR Ki 7 CHEMBL
D(2) dopamine receptor GPCR Ki 9.10 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 9.40 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.97 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.15 CHEMBL
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 7.80 IUPHAR
D(1A) dopamine receptor GPCR Ki 9.10 CHEMBL
D(3) dopamine receptor GPCR IC50 7.42 CHEMBL
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 IUPHAR
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 2C GPCR IC50 7.59 CHEMBL

External reference:

IDSource
4021367 VUID
N0000148786 NUI
D01164 KEGG_DRUG
352393 RXNORM
C0299792 UMLSCUI
CHEBI:31236 CHEBI
9SC PDB_CHEM_ID
CHEMBL1112 ChEMBL_ID
D000068180 MESH_DESCRIPTOR_UI
DB01238 DRUGBANK_ID
34 IUPHAR_LIGAND_ID
7477 INN_ID
82VFR53I78 UNII
60795 PUBCHEM_CID
17034 MMSL
231328 MMSL
45384 MMSL
d04825 MMSL
009852 NDDF
4021367 VANDF
406784005 SNOMEDCT_US
406785006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-8259 TABLET 5 mg ORAL ANDA 33 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-8375 TABLET 5 mg ORAL ANDA 32 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6509 TABLET 2 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6510 TABLET 5 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6511 TABLET 10 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6512 TABLET 15 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6513 TABLET 20 mg ORAL ANDA 31 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6514 TABLET 30 mg ORAL ANDA 31 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6655 TABLET 2 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6656 TABLET 5 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6656 TABLET 5 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-216 TABLET 2 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-216 TABLET 2 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-217 TABLET 5 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-217 TABLET 5 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-218 TABLET 10 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-218 TABLET 10 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-219 TABLET 15 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-219 TABLET 15 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-220 TABLET 20 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-220 TABLET 20 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-221 TABLET 30 mg ORAL ANDA 30 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-221 TABLET 30 mg ORAL ANDA 30 sections
ABILIFY HUMAN PRESCRIPTION DRUG LABEL 1 16590-323 TABLET 2 mg ORAL NDA 32 sections
ABILIFY HUMAN PRESCRIPTION DRUG LABEL 1 16590-745 TABLET 5 mg ORAL NDA 32 sections
Aripiprazole Human Prescription Drug Label 1 16714-141 TABLET 2 mg ORAL ANDA 31 sections
Aripiprazole Human Prescription Drug Label 1 16714-142 TABLET 5 mg ORAL ANDA 31 sections
Aripiprazole Human Prescription Drug Label 1 16714-143 TABLET 10 mg ORAL ANDA 31 sections
Aripiprazole Human Prescription Drug Label 1 16714-144 TABLET 15 mg ORAL ANDA 31 sections
Aripiprazole Human Prescription Drug Label 1 16714-145 TABLET 20 mg ORAL ANDA 31 sections